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 Introduction 1
1.1 Pulmonary surfactant 
 
Mammalian pulmonary surfactant (PS) is a mixture of proteins (10%) and lipids (90%) 
synthesized and secreted into the alveolar space by type II epithelial cells (Zuo et al. 
2008; Goss et al. 2013) (Figure 1.1A and B). Four classes of surfactant proteins are 
associated with surfactant lipids, named SP–A, SP–B, SP–C and SP–D, representing 
5%, 2%, 2% and 1% of the total PS composition by weight, respectively (Jobe and 
Ikegami 2001). The hydrophobic proteins SP–B and SP–C are necessary for the 
adsorption of the surfactant layer to the alveolar air–liquid interface, thus lowering the 
surface tension. The hydrophilic proteins SP–A and SP–D contribute to surfactant 
homeostasis and also play a role in innate immunity (Casals and Cañadas 2012).  
The main function of the PS is to ensure minimal surface tension within the lung to 
avoid collapse during respiration. Furthermore, by interacting with inhaled pathogens, 
the PS also participates in host defense (Clements 1977). PS deficiency is therefore 
associated with pulmonary diseases such as asthma, bronchiolitis, respiratory distress 
syndrome (RDS), cystic fibrosis and pneumonia (Griese 1999). A number of different 
exogenous surfactant preparations have been developed and tested in clinical trials (Fox 
and Sothinathan 2005). Curosurf®, a natural surfactant formulation derived from 
minced porcine lungs, is currently one of the leading surfactant products in the USA, 
and comprises a mixture of phospholipids and the hydrophobic surfactant proteins SP–B 
and SP–C (Fox and Sothinathan 2005). Surfactant formulations are indicated for the 
treatment of RDS, which affects ~1.5 million premature babies globally every year (Box 
1.1). RDS is a major PS deficiency disease caused by the structural immaturity of the 
lungs in premature infants, which makes it difficult to breathe, inhibits gas exchange 
and promotes alveolar collapse (Notter 2000). However, treatment becomes more 
difficult if the lungs are infected or if there are inflammatory or oxidative complications, 
because current surfactant preparations lack SP–A and SP–D (Zuo et al. 2008). The 
successful treatment of complex pulmonary diseases therefore requires the production 
of surfactant formulations whose composition matches natural PS as closely as possible 
(Robertson and Halliday 1998). 
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Figure 1.1: Synthesis and composition of pulmonary surfactant  
(A) PS is synthesized by type II epithelial cells, packaged into intracellular organelles called lamellar 
bodies and then secreted into the alveolar space to form the surfactant layer that reduces the surface 
tension in the alveoli during respiration. Adapted from Chen and Kolls (2010) with permission. (B) PS is 
composed of lipids (90%) and proteins (10%) distributed as shown. Reproduced from Jobe and Ikegami 
with permission. DPPC: dipalmitoylphosphatidylcholine, PC: unsaturated phosphatidylcholine, PG: 
phosphatidylglycerol, PL: phospholipids.  
 
1.2 Surfactant products in clinical use 
 
The exogenous surfactants tested in RDS clinical trials can be assigned to three groups. 
The first comprises modified natural surfactants of bovine or porcine origin, which 
contain a mixture of phospholipids but only the hydrophobic proteins SP–B and SP–C, 
e.g. Curosurf®, BLES®, Infasurf® and Survanta® (Fox and Sothinathan 2005). The 
second comprises the synthetic surfactants Surfaxin® and Venticute®. The former 
contains DPPC, phosphatidylglycerol (PG), palmitic acid and a protein analog KL–4 
(sinalputide) which mimics the activity of SP–B (Zuo et al. 2008; Lal and Sinha 2008). 
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The latter contains DPPC, PG, palmitic acid and recombinant human SP–C (Zuo et al. 
2008; Walther et al. 2014). Finally, the third group comprises protein–free synthetic 
surfactants featuring a mix of phospholipids and additives (e.g. ALEC® and Exosurf®) 
(Zuo et al. 2008) (Table 1.1). 
Clinical trials have been carried out to compare approved surfactant products for the 
treatment of neonates with RDS. The use of synthetic surfactants, which were initially 
promoted as a less expensive product with homogeneous composition and a low risk of 
contamination with animal pathogens, has declined due to their poor clinical 
performance and complex manufacturing process (Zuo et al. 2008; Halliday 2005). 
Synthetic surfactants should contain at least one hydrophobic protein or analog for 
optimal performance, but these are structurally complex or unstable in pure form 
(Curstedt and Johansson 2005). Although modified natural surfactants are more 
expensive (~$500 per dose for neonates) they also reduce mortality and pulmonary air 
leaks more successfully (Notter 2000; Egberts 1995). Nevertheless, there is a higher risk 
of contamination with pathogens when animal-derived products are used, and the 
modified natural surfactants have a low and variable protein content compared to 
natural surfactants. For example, Survanta® contains only ~12% of the SP–B content 
and ∼50% of the SP–C content compared to the endogenous bovine surfactant, whereas 
Curosurf® contains only ∼33% of the SP–B content and ∼50% of the SP–C content 
compared to the endogenous porcine surfactant (Zuo et al. 2008; Bernhard et al. 2000). 
The in vitro activity of animal-derived surfactants shows variable sensitivity to 
inhibition by plasma proteins, fatty acids and proteases that eventually inactivate 
endogenous PS, based on the different protein contents of these products, making them 
more resistant when the surfactant proteins are present in greater amounts (Zuo et al. 
2008; Seeger et al. 1993). But SP–D, a component of the innate immune system that 
helps to reduce lung inflammation, is not present in any of the surfactant products on the 
market due to its hydrophilic properties, which causes it to be lost during extraction 
from animal sources. The performance of surfactant products could therefore be 
improved by supplementing them with recombinant SP–D. 
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Table 1.1: Surfactant preparations derived from animal lungs and synthetic surfactants  
(A) Composition of current natural surfactant products on the global market and in clinical trials. (B) 
Synthetic surfactant on market and preparations evaluated in clinical trials at the production country. (*) 
Worldwide sales (updated from Fox and Sothinathan 2005 and Zuo et al. 2008). 
(A) Natural surfactants 
Generic  
Name 
Trade name Source Protein 
content 
(SP–B + SP–C) 
Lipid 
content 
(mg/ml) 
Dose 
volume 
(ml/kg) 
Status Production  
country 
Beractant Survanta® Bovine <0.5% 25 4 On 
 market 
USA (*) 
Poractant 
alfa 
Curosurf® Porcine ~1% 80 
 
1.3–2.5 On  
market 
Italy (*) 
Bov. lipid 
extract 
BLES® Bovine ~1% 27 
 
5 Clinical 
trial 
Canada 
Bovactant Alveofact® Bovine ~1% 41.7 1.2 Clinical 
trial 
Germany 
Calfactant Infasurf® Bovine 650g/ml 
 
33.3 3 Clinical 
trial 
USA 
Surfactant 
TA 
Surfacen Bovine <0.5% – 5 Clinical 
trial 
Japan 
(B) Synthetic surfactants 
Generic 
 name 
Trade name Composition Status Production  
country 
Pumactant ALEC DPPC and PG. 
Protein free 
Clinical trial UK 
Colfosceril 
palmitate 
Exosurf DPPC with cetyl 
alcohol and tyloxapol 
Clinical trial UK 
Lusulptide Venticute DPPC, PG, palmitic 
acid and recombinant 
SP–C 
Clinical trial Switzerland 
Lucinactant   Surfaxin DPPC, POPG, 
palmitic acid + KL–4  
 On market USA 
Aerosolized  
Lucinactant 
Aerosurf DPPC, POPG, 
palmitic acid + KL–4 
Clinical trial USA 
POPG: palmitoyloleoylphosphatidylglycerol. 
KL–4: synthetic peptide sinapultide that mimics the structural characteristics of SP–B. 
 
1.3 Surfactant protein D  
 
 Structural organization of SP–D 1.3.1
SP–D belongs to the family of mammalian collagenous Ca2+-dependent defense lectins 
called collectins (C-type lectin). This group includes SP–A, a serum mannose binding 
protein (MBL), collectin liver 1 (CL–L1), collectin placenta 1 (CL–P1), collectin–43 
(CL–43) and collectin–46 (CL–46) (Holmoskov 2000; Ohtani et al. 2001). Collectins 
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are soluble pattern recognition receptors (PRRs) in the innate immune system which 
bind to oligosaccharide structures on the surface of microorganisms, leading to their 
clearance through aggregation, opsonization, complement activation and phagocytosis 
(Holmoskov et al. 2000; Lu et al. 2002). SP–D comprises four domains: a cysteine 
linked N-terminal region required for the formation of intermolecular disulfide bonds, a 
triple-helical collagen region, an α-helical coiled coil neck peptide necessary for 
trimerization of SP–D and a C-terminal calcium-dependent carbohydrate-recognition 
domain (CRD) (Hakansson and Reid 2000). SP–D is one of the largest molecules found 
in the innate immune system. It is assembled as a trimer (129 kDa in total, comprising 
three identical 43-kDa polypeptide chains), but higher oligomerization states such as 
520-kDa dodecamers can also be formed (Hakansson and Reid 2000; Crouch 2000) 
(Figure 1.2). 
Like all collectins, SP–D is post-translationally modified, which includes disulfide bond 
formation at the N-terminal region as well as N-linked and O-linked glycosylation in the 
collagen region (Leth–Larsen et al. 1999; Vuk–Pavlovic et al. 2001).  
 
 
Figure 1.2: Oligomeric structure of SP–D 
SP–D assembles as a trimer, which forms higher oligomerization complexes such as dodecamers and 
multimers. Modified from from Wright (2005) with permission. NCD: N-terminal non-collagenous 
domain, CD:  collagenous domain, ND:  α-helical coiled coil neck domain, CRD:  carbohydrate-
recognition domain. 
 
 
NCD CD ND CRD 
Dodecamer Multimer 
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 Functional aspects of SP–D 1.3.2
SP–D is a soluble PRR of the innate immune system which plays a fundamental role in 
the protection of the lungs against respiratory infection by modulating cellular immune 
responses against infectious and allergenic agents. SP–D interacts as an opsonizing 
agent directly with carbohydrates on the surface of microbes including viruses, bacteria, 
yeast, and fungi (Crouch 2000; Lawson and Reid 2000; Crouch and Wright 2001). 
These interactions promote pathogen agglutination, phagocytosis, chemotaxis and the 
modulation of Toll-like receptor functions (Kishore et al. 2006) (Figure 1.3). The 
binding properties of SP–D are determined by the spatial distribution of the CRDs 
(Crouch 2006), which are oriented 180° in the dodecamer, conferring upon SP–D a 
higher capacity to mediate interactions between different ligands compared to other 
collectins. The binding of CRDs to oligosaccharides involves hydrogen bonds and the 
coordination of Ca
2+ 
ions in the binding site (Crouch 2005).   
Although the complete SP–D molecule is essential for high-affinity binding to 
lipopolysaccharide (LPS) on the surface of microbes, a truncated form of SP–D 
comprising the neck and carbohydrate-recognition domain (NCRD) can successfully 
reduce the total number of apoptotic macrophages during chronic lung inflammation in 
mice deficient for SP–D. NCRD is not glycosylated and does not require any other post-
translational modifications, but retains the biological activity of the full-size protein in 
vitro and in vivo (Strong et al. 2003) because it undergoes normal CRD folding, the 
coordination of calcium ions and ligand binding (Crouch et al. 2005; Shrive et al. 2003; 
Hakkanson et al. 1999; Strong et al. 2002). 
Full-size SP–D binds and agglutinates the bacteria Escherichia coli, Klebsiella 
pneumoniae and Pseudomonas aeruginosa (Kuan et al. 1992; Lim et al.1994; Kishore 
et al.1996), viruses such as Respiratory syncytial virus, Human immunodeficiency virus 
and Influenza virus A (Crouch 2000; Hickling et al. 1999; LeVine et al. 2000; Meschi et 
al. 2005; Kishore et al. 2006) and fungi such as Saccharomyces cerevisiae, Candida 
albicans and Criptpcoccus neoformans (van Rozendaal et al. 2000). In addition, full-
size SP–D and the truncated form NCRD interact with the dust mite Dermatophagoides 
pteronyssinus, the major cause of allergic asthma. Both SP–D forms can suppress 
allergic symptoms in sensitized mice by preventing the binding of allergen-specific IgE 
to the dust mites (Wang et al. 1996; Strong et al. 2003).  
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Figure 1.3: Immunoregulatory functions of SP–D 
SP–D binds to bacteria, viruses, allergens and apoptotic cells and acts as an opsonizing agent to enhance 
the uptake of these cells by the macrophages. The binding of SP–D to pathogens occurs by various 
mechanisms e.g. agglutination, phagocytosis and lysis. SP–D also has direct effects on immune cells and 
modulates the production of cytokines and inflammatory mediators. Adapted from Wright (2005) with 
permission.  
 
 Natural sources of SP–D  1.3.3
The structure of SP–D from human, murine, porcine and bovine sources has been 
studied to determine its function in the innate immune system (Leth–Larsen et al. 2005; 
Kotecha et al. 2013; Wu et al. 2005; Van Eijk et al. 2003). Human SP–D (hSP–D) is 
usually isolated from bronchoalveolar lavage during alveolar proteinosis (the abnormal 
accumulation of surfactant in the alveoli, interfering with gas exchange) followed by 
carbohydrate affinity chromatography (Dodagatta–Marri et al. 2014; Strong et al. 
1998). The use of natural SP–D to supplement PS formulations is the best option to 
ensure therapeutic efficiency because higher-order multimerization in the endogenous 
surfactant increases the number of SP–D binding sites to carbohydrate ligands on the 
surface of pathogens, achieving potent bacterial and viral agglutination effects (White et 
al. 2008). However, the SP–D concentration after lung lavage is low because the 
hydrophilic properties of SP–D cause most of the protein to be lost during extraction 
(Barberi et al. 2006). Animal sources also present a risk of contamination with 
pathogens as well as non-uniform SP–D composition, reflecting the different 
oligomerization states that form after extraction and purification (Clark and Reid 2003; 
Strong et al. 1998). 
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1.4 Heterologous SP–D production systems 
 
 Mammalian cell lines 1.4.1
One of the first in vivo assays using prematurely-delivered lambs demonstrated the 
positive effects of Survanta®, a natural commercial surfactant, supplemented with full-
size recombinant SP–D (rSP–D) produced by Chinese hamster ovary (CHO) cells. A 
dose of 2 mg/kg recombinant human SP–D improved the surfactant function by 
protecting the premature lung against inflammation induced by ventilation. This study 
was one of the first to indicate the benefits of adding full-size rSP–D to the natural 
surfactant product and its potential use for the treatment of pulmonary diseases (Ikegami 
et al. 2006; Sato et al. 2010; Hartshorn et al. 1996). The production of active 
therapeutic proteins depends not only on protein synthesis but also correct folding and 
post-translational modification, especially glycosylation (Jayapal et al. 2007). SP–D 
folds with the aid of disulfide bonds in the N-terminal region and the collagenous region 
also undergoes N-linked glycosylation (Crouch 2000). Therefore, SP–D is usually 
synthesized in mammalian cells because they produce authentic glycan structures. 
Despite the typical advantages of mammalian cells in terms of yields and post-
translation modifications (Kim et al. 2012; Thomas and Smart 2005), the production of 
rSP–D remains a challenge because it is not synthesized efficiently.  
The mammalian cell line that is most widely used for the production of full-length SP–
D is the CHO–K1 subclone (Kim et al. 2012). CHO cells can produce many 
biopharmaceutical products in the grams per liter yield range following extensive cell 
line and process optimization (Lai et al. 2013), but in the case of rSP–D the yields are 
typically 0.5–2.0 mg of purified protein per liter (Chiba et al. 2002). If we match the 
demand for rSP–D against the current annual use of Curosurf® for the treatment of 
RDS (McBean 2009) it would be necessary to produce 1.875–3.75 kg/year based on a 
single dose for the minimum demand and three doses for the maximum demand, in each 
case representing ~1.5 million premature babies (Salgado et al. 2014). Even if rSP–D 
could be produced by industrial fermentation in 20,000-liter bioreactors (Junker 2004; 
Porter et al. 2010), each campaign would only produce a maximum of 40 g of purified 
protein per campaign, so even with 100% success at the highest current yields this 
would require 47–94 campaigns per year to meet the annual demand for this protein 
(Salgado et al. 2014). 
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Human embryonic kidney cell line 293 (HEK293) has also been used to produce rSP–D 
and in this case the reported yields were in the range 1–5 mg/l (Van Eijk et al. 2011). 
Using the same assumptions as above, this suggests that a single campaign in a 20,000-
liter fermenter would yield 100 g of pure rSP–D, requiring 19–38 campaigns to meet 
annual demand (Salgado et al. 2014; Junker 2004; Porter et al. 2010). As well as the 
large volumes of mammalian cell culture required to produce sufficient amounts of rSP–
D to meet global demand, such cell lines also present an additional risk of 
contamination with animal pathogens, which increases the costs of downstream 
processing and purification, and hence the cost of the production facilities (Demain and 
Vaishnav 2009). However, mammalian cells are advantageous over natural sources of 
SP–D because they provide continuous and uniform amounts of protein over a short 
cultivation period and the source material is not scarce. SP–D yields could be improved 
in the future by medium optimization, the selection of better production cell lines and 
the optimization of cultivation strategies (Demain and Vaishnav 2009). 
 Escherichia coli 1.4.2
Escherichia coli was the first organism used for the production of therapeutic 
recombinant proteins and is still widely used today, particularly for the production of 
small proteins lacking glycan structures. Cultivation is simple and inexpensive, and 
large amounts of protein can be produced in a relatively short time (Demain and 
Vaishnav 2009). E. coli has been used successfully for the production of human, rat and 
mouse NCRD (White et al. 2008; Crouch et al. 2005; Strong et al. 2003; Crouch et al. 
2006; Shrive et al. 2003). The yields of purified mouse NCRD (5–10 mg/l) were about 
four times lower than human and rat NCRD, suggesting that the maximum yield of 
human NCRD is 40 mg/l in this system. The Arg–Ala–Lys (RAK) sequence from CL–
43 bovine serum collectin was inserted into the corresponding SP–D sequence and this 
modified protein was also expressed with a yield approaching 40 mg/l (Crouch et al. 
2005). Trimeric NCRD is a 60-kDa polypeptide but each molecule has the same activity 
as the trimeric full-size rSP–D which is 129 kDa (Strong et al. 2002). This means that 
every kg of the full-size product can be replaced with 470 g of the truncated derivative. 
On this basis, the annual demand for active rSP–D can be met by producing 0.881–
1.762 kg of NCRD (Salgado et al. 2014). Again assuming a campaign based on a 
20,000-liter bioreactor, the entire annual demand for NCRD could be met by 1–2 
campaigns (Salgado et al. 2014; Junker 2004; Porter et al. 2010). Several in vivo studies 
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have demonstrated the therapeutic effects of purified recombinant NCRD produced in 
E. coli in mouse models of infectious, allergic and inflammatory diseases. The 
administration of recombinant NCRD suppressed the development of allergy symptoms 
against Aspergillus fumigatus (Strong et al. 2002; Madan et al. 2001) and 
Dermatophagoides pteronyssinus (Wang et al. 1998; Seeger et al. 1993; Singh et al. 
2003). The intrapulmonary administration of recombinant NCRD also reduced the 
number of apoptotic and necrotic alveolar macrophages, helped to control asthma-
related inflammation and improved lung health in SP–D-deficient mice (Clark et al. 
2002). 
The successful preclinical testing of recombinant NCRD produced in E. coli 
demonstrates the suitability of this platform for the production of an active 
pharmaceutical ingredient for human use. The yields can be improved by optimizing 
gene expression and protein accumulation (e.g. by using different promoters to boost 
gene expression, incorporating a leader peptide to direct the protein into the periplasmic 
space or by expressing fusion proteins to increase product stability) and by improving 
the growth medium and process parameters (Demain and Vaishnav 2009). 
 Pichia pastoris 1.4.3
Yeast provide cost-effective production systems with high productivity and rapid 
growth like bacteria, but they are eukaryotic cells and can therefore fold complex 
proteins and carry out most forms of post-translational modification (Demain and 
Vaishnav 2009). Despite these advantages, recombinant SP–D is not yet produced in 
yeast, although Pichia pastoris has been used to produce truncated SP–D to enable the 
analysis of its crystal structure. The yield of human NCRD in P. pastoris was 7 mg/l 
(Hakkanson et al. 1999), which means that 140 g of purified NCRD could be produced 
by P. pastoris cells using a 20,000-liter fermenter (Salgado et al. 2014; Junker 2004; 
Porter et al. 2010). Based on the calculations presented above, this would require 6–13 
campaigns to meet annual demand (Salgado et al. 2014). The capacities of the 
production platforms are summarized in Table 1.2. 
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Table 1.2: The ability of heterologous production systems to meet the current global demand for 
recombinant SP–D 
The reported maximum yields of purified full-size recombinant SP–D and its truncated form (NCRD) in 
different heterologous production systems were used to estimate the number of campaigns required to 
meet annual demand assuming ~1.5 million premature babies require one treatment per year (minimum 
demand) or three treatments per year (maximum demand) and that each campaign has a production 
volume of 20,000 liters. The calculations are explained in detail in the Box 1.1. 
Heterologous 
production system 
Maximum reported 
yields (mg/l) 
Number of campaigns 
required to meet 
minimum annual 
demand
1
 
Number of campaigns 
required to meet 
maximum annual 
demand
2 
 Full-size SP–D   
CHO–K1 2 47 94 
HEK293 5 19 38 
 NCRD  
 
Escherichia coli 40 1 2 
Pichia pastoris 7 6 13 
1
Minimum annual demand is 1.875 kg rSP–D or 0.881 kg NCRD.  
2
Maximum annual demand is 3.75 kg rSP–D or 1.762 kg NCRD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box 1.1: Calculating the annual demand for SP–D 
To calculate the annual demand for SP–D RDS was used as a case study because this is the only disease 
for which surfactant products are currently indicated. There are ~15 million premature births every year 
(Blencowe et al.  2012) and based on USA data only 10% of the premature babies are affected by RDS 
(Raj and Whrite 2010). Therefore ~1.5 million babies were used as the basis for our annual demand 
calculations. 
Surfactants are administered on the basis of body weight so to simplify the calculations the mean body 
weight of a premature baby was determined based on USA data from the Centers of Disease Prevention 
and Control (Martin et al. 2012). A premature birth was defined as any baby born weighing less than 2.5 
kg and the mean weight was calculated based on averaged frequency data (Table F in Martin et al. 2012) 
resulting in an average premature weight of 2 kg. The recommended single dose of Curosurf® per kg 
body weight (Cornerstone Therapeutics Inc. 2010) contains 2.5 mg of protein (SP–B plus SP–C) which 
represents a dose of 5 mg for a 2-kg premature baby. For more complicated cases, two additional doses 
are recommended within 72 h, so a three dose regimen would administer 10 mg of protein, given that the 
second and third doses are half strength. Because SP–B and SP–C together account for 40% of natural 
surfactant protein whereas SP–D accounts for 10%, the corresponding „ideal‟ doses of SP–D to match 
the proportions present in natural surfactant (Jobe and Ikegami 2001) would be 1.25 mg for one dose 
and 2.5 mg for three doses. Multiplying these amounts by 1.5 million premature babies at risk of RDS, 
the minimum and maximum annual demands are 1.875 and 3.75 kg SP–D, respectively. 
For the truncated product (NCRD), the same amount of functional protein would have 47% of the mass 
(Strong et al. 2002), so the minimum and maximum annual demands are reduced to 0.881 and 1.762 kg, 
respectively. 
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As shown in Table 1.2, the global annual demand for recombinant SP–D in the context 
of RDS could be meet in theory by weekly campaigns in mammalian cells and 1–2 
large-scale campaigns in E. coli. However, recombinant SP–D is also required for the 
treatment of other pulmonary diseases such as asthma and cystic fibrosis and in this case 
mammalian and microbial platforms cannot thus far produce sufficient quantities of the 
protein. Therefore, this PhD project introduced plants as an alternative production 
platform for SP–D. The goal was to evaluate the production of recombinant human SP–
D (rhSP–D) in plants and determine their capacity to meet the growing demand for this 
protein.  
1.5 Molecular farming – production of recombinant proteins in 
plants 
 
Molecular farming is the use of genetically engineered plants and plant cell suspension 
cells as platform for the production of recombinant pharmaceutical proteins on a large 
scale and at low costs (Fischer et al. 2013; Schillberg et al. 2013). Plants have several 
advantages over mammalian and bacterial platforms for recombinant SP–D production. 
First, plants have much lower manufacturing costs than mammalian, bacterial and insect 
bioreactors, which require expensive growth media and complicated purification 
processes (Kostandini et al. 2006). Second, plants have the ability to perform complex 
post-translational modifications, which are important for the biological activity of many 
mammalian proteins (Tremblay et al. 2010). Third, proteins can be targeted to 
intracellular compartments, affecting post-translational modification and yields. Fourth, 
plants are far less likely to introduce human or animal pathogens during downstream 
processing, which is a concern when using mammalian cells as production hosts 
(Jouzani and Tohidfar 2013). Finally, the general eukaryotic protein synthesis pathway 
is well conserved between plants and animals, so plants are potentially able to fold and 
assemble multimeric proteins like SP–D (Fischer et al. 2009). One of the most widely 
used plant-based expression platforms is tobacco, a plant with a high biomass yield that 
is neither a food nor a feed crop, reducing the likelihood of transgenic material 
contaminating the food chain. Some examples of recombinant plant-derived 
pharmaceutical proteins are described in Table 1.3 
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Table 1. 3: Recombinant plant-derived pharmaceutical proteins 
Recombinant protein products in development or on the market (adapted from Broz et al. 2013 and 
Everett et al. 2012). 
Manufacturer Plant Product Indication 
 
Clinical stage 
Medicago Tobacco Vaccine 
 
H5N1 Influenza 
H1N1 Influenza 
Phase II 
Planet 
Biotechnology 
Tobacco Vaccine Dental caries  On market 
Protalix Carrot  Glucocerebrosidase 
Acetylcholinesterase 
Gaucher‟s disease 
biodefense 
FDA approved 
Phase I 
Sembiosys Safflower Insulin 
Apoliprotein A1 
Diabetes 
cardiovascular 
Phase III  in planning 
Preclinical complete 
Ventria  
Bioscience 
Rice rh–lactoferrin 
rh–albumin 
Diarrhea 
replacement for HSA  
Phase II 
Phase I 
Arizon State 
University 
Potato Vaccine 
 
Hepatitis B  
Norwak virus 
Phase I 
Phase I–II 
Biolex Lemna Alpha interferon  Hepatitis B 
Hepatitis C 
cancer 
Phase II 
FDA: Food and Drug Administration.  
rh: recombinant human protein. 
HSA: human serum albumin. 
 
1.6 Aim of this PhD thesis 
 
The aim of this thesis was to determine whether three rhSP–D variants (full-size hSP–D, 
its truncated form (hNCRD) and a hNCRD–DsRed fusion protein) could be produced in 
tobacco by: 1) identifying the best strategy for high level rhSP–D production, 2) 
analyzing protein integrity using biochemical assays, and 3) confirming the biological 
activity and functionality of the rhSP–D forms. This PhD thesis is therefore organized in 
two parts (Figure 1.4): 
 
1. Establishment of a plant expression platform for high-level rhSP–D production  
       In the first part, a panel of expression constructs was designed to express the three 
rhSP–D variants (full-size hSP–D, hNCRD and the hNCRD–DsRed fusion protein) in 
Nicotiana tabacum plants. The constructs included a His6 tag sequence enabling protein 
purification by immobilized metal ion affinity chromatography (IMAC). The His6 tag 
was added either to the C-terminal or N-terminal of the proteins in order to assess the 
effect of the tag on protein function. Constructs without tags were created and the 
proteins were purified using N-acetylmannosamine (ManNAc). Aiming to find the best 
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cell compartment for high-level rhSP–D production, all the constructs mentioned above 
were designed with a signal peptide sequence that directs the recombinant protein into 
the apoplast. Additionally, intracellular cytosolic versions were generated by omiting 
the signal peptide. The best targeting strategy was evaluated based on the accumulation 
levels and protein integrity achieved after transient expression. Constructs achieving the 
highest protein expression levels were selected for stable transformation in tobacco 
plants. 
 
2. Characterization of rhSP–D variants in terms of C-type lectin activity 
 
After transient expression and purification, the functionality of the rhSP–D variants was 
examined based on their C-type lectin activity. For this purpose, each form was 
evaluated to determine its ability to bind different saccharides (by competitive ELISA) 
and its ability to bind and agglutinate bacteria. The final functional rhSP–D variants 
were tested in a thermal stability assay for two months at different temperatures in order 
to find the best condition that maintains the structure and activity of the rhSP–D variants 
in long-term storage. 
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Part 1 
Establishment of a plant expression platform for high-level rhSP–D production 
Part 2 
Characterization of rhSP–D variants in terms of C-type lectin activity 
hNCRD–DsRed 
fusion protein  
hNCRD  Full-size hSP–D  
With  
His6 tag 
Without 
His6 tag 
With  
His6 tag 
Without 
His6 tag 
With His6 
tag 
Apoplastic version  
Transient and stable transformation in N. tabacum 
Transient expression in 
N. tabacum 
Purification by IMAC or ManNAc  Purification by IMAC  
Bacterial agglutination assay 
Apoplastic and cytosolic versions  
Thermal stability assay 
Vector design and cloning 
Competitive ELISA 
Figure 1.4: Schematic diagram showing the structure of this PhD thesis 
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 Materials and methods 2
2.1 Materials 
 Chemicals and consumables  2.1.1
The chemicals used in this project were purchased from the following companies: 
Amersham Pharmacia Biotech (Freiburg), BioRad (München), Dako (Hamburg), 
Dianova (Hamburg), Duchefa (Haarlem, Netherlands), Eurofins MWG (Ebersberg), GE 
Healthcare (Freiburg), Invitrogen (Darmstadt), Jackson ImmunoResearch (West Grove, 
USA), Macherey–Nagel (Düren), Merck (Darmstadt), New England Biolabs–NEB 
(Frankfurt), R&D systems (Wiesbaden–Nordenstadt), Roche (Mannheim), Sigma–
Aldrich (Heidelberg) and VWR (Darmstadt). Consumables were purchased from the 
following companies: Eppendorf (München), GE Healthcare (Freiburg), GenScript 
(Piscataway, USA), Greiner Bio–One (Solingen), Macherey–Nagel (Düren), Millipore 
(Eschborn), Promega (Mannheim), Qiagen (Hilden), Roth (Karlsruhe), Spectrum 
Laboratories (Rancho Dominguez, USA) and Whatman (Dassel). 
 Buffers, media and solutions 2.1.2
Solutions, buffers and media were prepared according to Sambrook and Green (2012). 
Media for cultivating bacteria were sterilized by autoclaving (2 bar, 25 min, 121°C). 
Heat-sensitive components, such as antibiotics, were added to the media after 
autoclaving and cooling to 50°C.  
 Matrices and membranes 2.1.3
N-acetyl-D-mannosamine (Sigma–Aldrich) coupled Sepharose CL–4B columns (GE 
Healthcare) were used for the purification of recombinant proteins based on 
carbohydrate affinity by N-acetylmannosamine chromatography (2.2.5.1,  2.2.5.2). NTA 
agarose (Macherey–Nagel) and Chelating Sepharose Fast Flow (GE Healthcare) resins 
were used for the purification of recombinant His6-tagged proteins by immobilized 
metal ion affinity chromatography (2.2.5.3). Immobilon–P transfer membranes (PVDF, 
0.45 μm Millipore), Hybond C nitrocellulose membranes (0.45μm, GE Healthcare) and 
Whatman N°1 paper (Whatman) were used for immunoblot analysis (2.2.4.4).  
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 Reaction kits and enzymes  2.1.4
Enzymes and buffers (NEB) were used for DNA digestion and ligation according to the 
manufacturer‟s instructions. Thermus aquaticus (Taq) DNA polymerase was used for 
PCR experiments (2.2.1.1, 2.2.1.2). The Nucleospin Plasmid Kit and Extract II Kit 
(Macherey–Nagel) were used for plasmid isolation and DNA fragment purification, 
respectively (2.2.1.4, 2.2.1.5). 
 Antibodies and substrates  2.1.5
Polyclonal F(ab′)2 anti-human SP–D capture antibodies from rabbit clone K477 (kindly 
provided by Dr. Grith Sorensen, Institute of Molecular Medicine, University of 
Southern Denmark) and biotin-labeled monoclonal anti-human SP–D antibody 
(hybridoma 246–04)  from mouse clone 10B2 (Dianova) were used in the ELISA 
experiments (2.2.4.5). The same monoclonal anti-human SP–D antibody (without 
biotin-labeled) and a polyclonal rabbit anti-mouse immunoglobulin–alkaline 
phosphatase conjugate (Ig–AP, Dako) were used for immunoblot analysis (2.2.4.4). 
Para–nitrophenyl phosphate (pNPP) (Sigma–Aldrich) and p–nitroblue tetrazolium 
chloride/5-bromo-4-chloro-3-indolylphosphate (NBT/BCIP, BioRad) were used as 
chromogenic substrates for the ELISA and immunoblot experiments, respectively. 
 Plants  2.1.6
Nicotiana tabacum L. cv. Petit Havana SR1 was used for transient expression and stable 
transformation (2.2.3.2, 2.2.3.3, 2.2.3.4).  
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 Equipment, apparatus and accessories 2.1.7
 
Device   Manufacturer 
ÄKTA explorer 10  GE Healthcare  
DNA–sequencing machine 3700 DNA analyzer Applied Biosystems, Darmstadt 
BigDyeTM cycle–sequencing terminator chemistry Applied Biosystems, Darmstadt 
DNA gel electrophoresis apparatus,  Mini Protean II BioRad 
Cell counter, CASY 1 TT  Roche 
Clean bench  Kojair, Nideggen 
Centrifuges:                  Avanti J–26 XPI  Beckman, USA 
 5415 D and 5415 R Eppendorf 
 Multifuge 3S and 3S–R Heraeus, Hanau 
Cuvettes 0.2 cm or 0.4 cm  BioRad 
ELISA plates washer ELx405   Bio-Tek, Bad Friedrichshall 
ELISA reader   Synergy HT from Bio–Tek  
Electroporation apparatus, Multiporator Eppendorf 
InnovaTM 4340 incubator shaker  New Brunswick scientific, Nürtingen 
PCR Thermocyclers:      Primus and Primus 96 plus MWG–Biotech 
 Mastercycler Personal Eppendorf  
 DNA Egine MJ Research Inc, USA  
Pipettes P20; P200, P1000  Gilson, Middleton, USA 
Rotors:                           JA–25.50, JA–10 Beckmann Coulter, Krefeld 
                                     #75006445, #3057 Heraeus, Hanau 
Spectrophotometer:         NanoDrop® ND–1000 
UV/Vis 
NanoDrop Technologies, USA 
                                         Uvikon 930 Kontron, Neufahrn 
Software:                      Window XP operating system Microsoft, USA 
                                         Microsoft Office 2010 Microsoft, USA 
                                       Adobe Photoshop CS2 Adobe, USA 
                                         Clone manager suite 8 Invitrogen, USA 
                                     EndNote Thomson Reuters, USA 
                                         OriginPro 8.1G Microcal Software, Inc, USA 
                                         Cromas  Microcal Software, Inc, USA 
 Lasergene® SeqMan v 7.0.0  DNASTAR, USA 
 Editseq DNASTAR, USA 
Thermomixer comfort shaker  Eppendorf 
UV–Transilluminators:    Wavelength 302 nm Herolab, Wiesloch 
                                          UV–chamber BioRad 
Vacuum filtration unit  Sartorius, Göttingen 
Vacuum pump membrane  Vacuumbrand, Wertheim 
Vortex Genie 2   Scientific Industries, Bohemia, USA  
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 Bacterial and yeast strains  2.1.8
Methyltransferase-deficient chemically-competent Escherichia coli cells (NEB) were 
used as host cells for intermediate cloning constructs (2.2.1.8) according to the 
manufacturer‟s recommendations. E. coli DH5α [genotype F– (80d lacZΔM15) 
Δ(lacZYA–argF) U169 endA1 recA1 hsdR17 (rk– mK+) deoR thi–1 supE44 gyrA96 
relA1 λ–] was used to perform the bacterial agglutination assay (2.2.6.2). 
Agrobacterium tumefaciens GV 3101 (pMP90RK Gm
R
, Km
R
, Rif
R
; Koncz and Schell, 
1986) was used for Agrobacterium-mediated gene transfer following electroporation 
(2.2.2.4).  
2.2 Methods 
 Molecular biology methods 2.2.1
General recombinant DNA techniques, e.g. restriction enzyme digestion, DNA ligation 
and DNA agarose gel electrophoresis, were performed according to the standard 
protocols described by Sambrook and Green (2012). 
2.2.1.1 PCR amplification  
Polymerase chain reactions were performed in 0.2-ml Eppendorf tubes, using 
thermostable Thermus aquaticus (Taq) DNA polymerase, oligonucleotides synthesized 
by Eurofins MWG (Table 7.1) and a thermal cycler. The PCR components are described 
in Table 2.1 and the protocol in Table 2.2. 
 
Table 2.1: PCR components 
Component Final concentration 
10x PCR buffer 1x 
50 mM MgCl2 1.5 Mm 
10 mM dNTPs 0.2 mM each dNTP 
10 pmol/µl forward primer 1 pmol 
10 pmol/µl reverse primer 1 pmol 
Template DNA  ~10–30 ng 
Taq DNA polymerase (5 U/ml) 2.6 U/reaction 
ddH2O to 50 µl 
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Table 2.2: Standard PCR protocol 
Reaction step Temperature [°C] Time [s] Cycle repetition 
Initial denaturation 95 300 1 
Denaturation 95 10  
Primer annealing X X 28 
Extension 72 60  
Final extension 72 900 1 
Storage 20   
 
2.2.1.2 Colony PCR 
Colony PCR was used for the rapid identification of recombinant E. coli (2.2.2.2) and 
recombinant A. tumefaciens (2.2.2.4) as described by Jesnowski et al. (1995). Isolated 
colonies were picked using sterile tips and suspended in 10 μl ddH2O in 0.2-ml 
Eppendorf tubes containing 15 μl of the PCR master mix. The PCR components are 
described in Table 2.3 and the protocol in Table 2.4. 
 
Table 2.3: Colony PCR components 
Component Final concentration 
10x PCR buffer 1x 
50 mM MgCl2 1.5 Mm 
10 mM dNTPs 0.2 mM each dNTP 
10 pmol/µl forward primer 0.4 pmol 
10 pmol/µl reverse primer 0.4 pmol 
Template DNA  ~0.1–10 ng 
Taq DNA polymerase (5 U/ml) 1.25 U/reaction 
ddH2O to 25 µl 
 
Table 2.4: Standard Colony PCR protocol 
Reaction step Temperature [°C] Time [s] Cycle repetition 
Initial denaturation 95 300 1 
Denaturation 95 60  
Primer annealing X X 28 
Extension 72 60  
Final extension 72 900 1 
Storage 20   
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2.2.1.3 Restriction digestion of DNA  
Restriction endonucleases, reaction buffers and bovine serum albumin (BSA) solution 
were obtained from NEB. The enzymatic restriction of DNA was carried out according 
to the manufacturer‟s instructions. Approximately 1 µg of DNA was cut with 1–5 U of 
the corresponding restriction enzyme(s). Preparative gel electrophoresis (2.2.1.5) was 
used to isolate and purify the DNA digestion products. The DNA fragments in the 
agarose gel were visualized using a UV transilluminator at 302 nm and were excised 
with a sterile scalpel. The excised fragment was purified using the NucleoSpin Extract 
II Kit (Macherey–Nagel) (2.1.4) according to the manufacturer‟s instructions. The 
concentration of the recovered DNA was determined using a NanoDrop® ND–1000 
spectrophotometer (Nanodrop technology). 
2.2.1.4 Isolation of plasmid DNA from  E. coli  
High-quality plasmid DNA was purified from recombinant E. coli cultivated overnight 
in 5 ml lysogeny broth (LB) (160 rpm, 37°C) (2.2.2.2). The plasmid was isolated using 
the NucleoSpin Plasmid Kit (Macherey–Nagel) according to the manufacturer‟s 
instructions (2.1.4). The purity and yield of the purified plasmid DNA was determined 
by reading the UV absorbance at 260 and 280 nm with a NanoDrop ND–1000 
spectrophotometer (Nanodrop technology) according to Sambrook and Green (2012). 
The purified plasmid was verified by a control restriction enzyme digestion followed by 
agarose gel electrophoresis. 
2.2.1.5 Analytical agarose gel electrophoresis 
Plasmid DNA (2.2.1.4), PCR fragments (2.2.1.1 and 2.2.1.2) and enzymatically 
digested DNA (2.2.1.3) were separated in 0.8–1.2% (w/v) agarose gels applying an 
electrical field (120 V, 45–50 min) in 1x Tris borate EDTA (TBE) buffer. The 
preparation of agarose gels and electrophoresis of the samples were carried out as 
described by Sambrook and Green (2012). Ethidium bromide (0.1 μg/ml) was added to 
the gel during preparation. Samples were mixed with 10x loading buffer and 7 µl DNA 
molecular markers, e.g. 1-kb ladder (Fermentas) or 100-bp ladder (Roth), were used to 
determine the size of the DNA fragments. DNA bands were visualized on a UV 
transilluminator at 302 nm and documented using universal hood II for Gel Doc XR 
(BioRad). 
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10x TBE electrophoresis buffer (pH 8.3) 
 
Tris base     900 mM 
Boric acid     900 mM 
EDTA       25 mM 
 
10x loading buffer         
 
Bromphenol blue 0.1 % (w/v)     
Xylene cyanol 0.1 % (w/v)     
Glycerol 50 % (w/v) 
Diluted in 1x TBE        
 
2.2.1.6 Ligation of DNA fragments 
Digested DNA fragments and vectors were ligated in a 3:1 molar ratio using 1 μl Quick 
T4 DNA ligase (NEB) according to the manufacturers‟ recommendations. The final 
volume of the ligation mixture was adjusted to 20 μl with ddH2O. Ligations were 
carried out for 1 h at room temperature or overnight at 15°C before transformation 
(2.2.2.1).  
2.2.1.7 DNA sequencing  
Fluorescent chain-terminating dideoxynucleotides were used for DNA sequencing 
(Sanger et al. 1977) using the Applied Biosystems 3700 DNA analyzer and BigDye
TM
 
terminator sequencing kit from Applied Biosystems. Sequencing was carried out by the 
Fraunhofer IME sequencing service. The sequence chromatograms were visualized with 
Chromas software (Microcal Software) and evaluated using Clone Manager Suite v8 
(Invitrogen), Lasergene v7.0.0 SeqMan and EditSeq (DNASTAR). Oligonucleotides for 
sequencing were prepared by Eurofins MWG (Annex, Table 7.1). 
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2.2.1.8 Generation of expression constructs 
The cDNAs encoding the full-size hSP–D, hNCRD and the hNCRD–Dsred fusion 
protein were synthesized by GenScript® using the full-size hSP–D sequence (GenBank 
AAB59450.1) as a template (Annex, Figure 7.2). The plant expression vector pTRApt, a 
derivate of pPAM (GenBank AY027531, Dr. Rademacher, Institute for Biology VII, 
RWTH Aachen University) was used to express the different SP–D constructs (Annex, 
Figure 7.1). The final expression constructs were verified by sequencing. 
 
 Microbiological methods 2.2.2
2.2.2.1 Transformation of E. coli by heat shock  
Chemically-competent E. coli cells (2.1.8) were thawed on ice for 5–10 min and mixed 
gently with either plasmid DNA (up to 200 ng) (2.2.1.4) or DNA ligation products 
(2.2.1.6) as described by Sambrook and Green (2012). The cells were stored on ice for 
30 min, followed by a heat shock at 42°C for 90 s, then immediately placed on ice for 5 
min. For regeneration, 450 μl SOC medium was added to the cells followed by 
incubation for 1 h at 37°C. After incubation, cells were plated on LB medium 
supplemented with appropriate antibiotics and incubated overnight at 37°C. 
 
SOC medium (pH 7.4) 
 
Yeast extract 0.5 % (w/v) 
NaCl 0.05 % (w/v) 
Peptone 2 % (w/v) 
Glucose 20 mM 
KCl 2.5 mM 
MgCl2 20 mM 
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2.2.2.2  Cultivation of E. coli and long-term storage  
A single positive E. coli colony from the heat-shock transformation (2.2.2.1) was 
inoculated into 5 ml LB plus antibiotics plus 100 µg/ml ampicillin and grown overnight 
at 160 rpm and 37°C. The cells were harvested by centrifugation (4000 x g, 10 min, 
room temperature) and resuspended in 2 ml of fresh LB. Glycerol stocks were prepared 
by mixing 700 μl of the bacterial suspension with 300 μl 50% (v/v) sterile glycerol and 
storing at –80°C. 
 
Lysogeny broth (pH 7.4) 
 
Peptone     1.0 % (w/v) 
Yeast extract          0.5 % (w/v) 
NaCl                1.0 % (w/v) 
 
2.2.2.3 Preparation of electrocompetent A. tumefaciens  
A single colony of A. tumefaciens strain GV3101 was inoculated into 10 ml YEB–Rif–
Km–Carb medium and grown for 48 h at 160 rpm and 28°C. A 1-ml aliquot was 
transferred to an Erlenmeyer flask containing 100 ml of fresh YEB–Rif–Km–Carb 
medium and cultivated for 20 h at 160 rpm and 28°C until the OD600 reached 1–1.5. The 
bacterial suspension was transferred to ice for 15 min and harvested by centrifugation 
for 5 min at 4000 × g and 4°C followed by three washing steps with 100 ml of ice-cold 
ddH2O and one with 100 ml ice-cold sterile 10% (v/v) glycerol. Finally, the bacterial 
cells were resuspended in 500 μl of sterile 50% (v/v) glycerol, and aliquots were frozen 
immediately in liquid nitrogen and stored at –80°C.  
 
YEB–Rif–Km–Carb medium 
 
Nutrient broth 0.5% (w/v) 
Yeast extract  0.1% (w/v)  
Peptone  0.5% (w/v)  
Sucrose  0.5% (w/v)  
 
After autoclaving and cooling to 55°C, the medium was supplemented with 2 mM 
MgSO4, 25 μg/ml rifampicin, 25 μg/ml kanamycin and 50 μg/ml carbenicillin.
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2.2.2.4  Transformation of A. tumefaciens by electroporation 
A thawed aliquot of electrocompetent A. tumefaciens cells (2.2.2.3) was mixed with 
0.2–0.4 μg of plasmid DNA (2.2.1.4) and placed on ice for 5 min. The mixture was then 
transferred to a pre-chilled electroporation cuvette and placed into the electroporator. 
After a current pulse (2.5 kV, 5 ms), the cells were diluted in 900 μl of SOC medium in 
a 2-ml Eppendorf tube and incubated for 1 h at 160 rpm and 28°C. Finally, 1–10 μl of 
the cells was plated on YEB–Rif–Km–Carb agar plates and incubated for 2–3 days at 
28°C. The resulting colonies were screened by colony–PCR (2.2.1.2) to confirm the 
presence of the insert. Positive colonies were grown in 5 ml YEB–Rif–Km medium 
overnight at 160 rpm and 28°C. Glycerol stocks were prepared by mixing fresh cell 
suspensions with 50% (v/v) sterile glycerol followed by storage at –80°C.  
2.2.2.5 Preparation of recombinant A. tumefaciens for plant transfection 
Recombinant A. tumefaciens (2.2.2.4) was used for transient expression (2.2.3.2, 
2.2.3.3) and stable transformation of (2.2.3.4) tobacco (N. tabacum  cv. Petit Havana 
SR1) plants according to Kapila et al. (1997) and Vaquero et al. (1999). A 5-μl aliquot 
of frozen cells (glycerol stock) was inoculated into 5 ml YEB–Km–Rif–Carb medium 
and incubated overnight at 160 rpm and 28°C. The culture was supplemented with 10 
mM glucose, 10 mM MES and 20 μM acetosyringone, and incubated as described 
above. The next day (OD600 = 3) the cells were harvested by centrifugation for 15 min at 
4000 × g at room temperature and resuspended in 2x infiltration medium until the OD600 
reached ~1.0. Acetosyringone was added to a final concentration of 200 mM. The 
culture was incubated at room temperature for 1 h before the infiltration of tobacco 
leaves. 
 
Infiltration medium 
  
MS basic salts  0.43% (w/v) 
Glucose  20 mM  
Sucrose  10% (w/v)  
Acetosyringone  200 µM  
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 Plant transformation methods 2.2.3
2.2.3.1 Growth and maintenance of N. tabacum plants 
Wild-type and transgenic N. tabacum cv. Petit Havana SR1 plants were grown in a 
greenhouse in ED73 standard soil (Patzer) containing 0–30% (v/v) sand. The 
greenhouse was held at 24°C, 70–90% humidity and benefited from sunlight plus 
additional illumination of 10000 lux with a 16-h photoperiod. To avoid cross-
pollination, flowers were protected with plastic bags with micropores. Mature, dried 
seeds were stored in paper bags at room temperature. 
2.2.3.2 Syringe agroinfiltration of N. tabacum plants 
For small-scale recombinant protein expression and evaluation, plants were transfected 
by agro-injection. Briefly, A. tumefaciens suspensions (2.2.2.5) were applied directly 
into the intracellular space of N. tabacum cv. Petit Havana SR1 leaves using a syringe 
without a needle. The injected plants were incubated for 5 days with a 16-h photoperiod, 
at 7500 lux and 24°C. 
2.2.3.3 Leaf disc agroinfiltration 
To screen larger numbers of transgenic N. tabacum cv. Petit Havana SR1 plants, leaf-
disc agroinfiltration was carried out according to Piotrzkowski et al. (2012). Tobacco 
leaf discs were removed using a cork borer, fixed in a custom-made leaf disc holder and 
positioned in an infiltration tank containing 120 ml of A. tumefaciens suspension 
(2.2.2.5). The leaf discs were vacuum infiltrated for 25 min at 50 mbar. After 
infiltration, the leaf discs were incubated for 5 days with a 16-h photoperiod, at 7500 
lux and 24°C, in Petri dishes containing 1.5% (w/v) water–agar. 
2.2.3.4 Stable transformation of N. tabacum 
Seeds of wild-type N. tabacum  cv. Petit Havana SR1 plants were germinated under 
sterile conditions on MS I medium. The seeds were sterilized using 70% (v/v) ethanol 
for about 1 min and then washed with ddH2O. The youngest leaves (up to 6 cm in 
length) were harvested and used for transformation. The leaves were cut into small 
pieces (0.5–1 cm2) and transferred into sterile glasses containing 100 ml of recombinant 
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A. tumefaciens suspension and incubated for 10–15 minutes at room temperature. The 
leaf pieces were then transferred onto Whatman papers wetted with sterile water in Petri 
dishes and incubated for 2 days at 24°C in the dark. Later, the leaf pieces were 
transferred onto MS II plates and incubated for 3–4 weeks with a 16-h photoperiod at 
24°C. After sprouting, the shoots were cut and transferred onto MS III plates and 
incubated under the same conditions for 10–14 days until roots emerged. The initial 
transgenic plants (T0) were transferred into Duchefa Weck glasses (height 140 mm, base 
90 mm, top and cover 115 mm) containing MS III medium and incubated with a 16-h 
photoperiod at 24°C. Two weeks later, the transgenic plants were transferred to ED73 
(Patzer KG, Sinntal–Jossa) soil and cultivated with a 16-h photoperiod at 10,000 lux 
(plus sunlight), 25°C and 70–90% humidity. To avoid cross-pollination the flowers 
were enclosed in plastic bags with micropores before self-pollination. Seeds from T1 
transgenic plants were stored in the Fraunhofer IME internal seed bank. The zygosity of 
the next generations of transgenic plants was evaluated by segregation analysis.  
 
MS I medium 
 
MS + vitamins                  4.4 % (w/v) 
Sucrose 20 % (w/v) 
Thiamine–HCl                      0.2 mg/l 
Agar 8.0 % (w/v) 
                                
Adjust pH to 5.8 with KOH /NaOH and autoclave for 35 min at 121°C and 1 bar 
 
MS II medium 
MS I medium supplemented with: 
 
BAP 1 mg/l 
NAA 0.1 mg/l 
 
BAP = 6-benzylaminopurine, NAA = 1–naphthaleneacetic acid. Adjust pH to 5.8 with 
KOH/NaOH and autoclave for 35 min at 121°C and 1 bar. After autoclaving add (filter 
sterilized) cefatoxime sodium (200 mg/l) and the selection reagent were added. 
 
MS III medium 
MS I medium supplemented after autoclaving with cefatoxime sodium (200 mg/l) and 
the selection reagent. 
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 Protein analysis 2.2.4
2.2.4.1 Sample preparation   
Total soluble proteins were extracted from tobacco leaves by grinding them in liquid 
nitrogen to a fine powder using a mortar and pestle, adding 2 ml extraction buffer per 
gram of leaf material, and centrifuging for 20 min at 40,000 x g and 4°C. Finally the 
soluble proteins were passed through a 0.45-µm filter (Carl–Roth). 
 
Protein extraction buffer (pH 5.4) 
 
 
 
10x PBS 
 
NaCl 1.37 mM 
KH2PO4 15 mM 
Na2HPO4 81 mM 
KCl 27 mM 
2.2.4.2 Polyacrylamide gel electrophoresis 
The integrity and quantity of recombinant proteins was analyzed by sodium 
dodecylsulfate polyacrylamide gel electrophoresis (SDS–PAGE) (Table 2.5) essentially 
according to Laemmli (1970) in a BioRad Mini Protean II chamber for 40–50 min at 
70–80 mA/gel in 1x SDS running buffer. Unpurified and purified samples were detected 
by Coomassie staining, silver staining or immunoblot. 
 
10x SDS running buffer 
 
Tris 250 mM 
Glycine 1.92 M 
SDS 1% (w/v) 
  
10x non-reducing SDS–PAGE  
Sample buffer (pH 8.3) 
 
Tris–HCl 62.5 mM pH 6.8 
SDS 2% (v/v) 
Glycerol 10% (v/v) 
Bromophenol blue 0.05% (w/v) 
Na2S2O5 10 mM 
In 1x PBS  
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Table 2.5: Composition of SDS–PAGE gels 
Components Separating gel Stacking gel 
Tris–HCl 38% (v/v), 1 M (pH 8.8) 12% (v/v), 1 M (pH 6.8) 
SDS 0.1% (w/v) 0.2% (w/v) 
Acrylamide 12% (w/v) 4% (w/v) 
TEMED 0.1% (v/v) 0.1% (v/v) 
APS 0.6% (w/v) 0.1% (w/v) 
 
2.2.4.3 Coomassie and silver staining 
Non-specific staining of recombinant proteins was carried out as described by Fairbanks 
et al. (1971). The gel was overlaid with solution A and heated in a microwave at 
maximum power to boiling point. After 5 min, the solution A was decanted, the gel was 
washed with ddH2O and overlaid with solution B and reheated to boiling point. The 
same steps were also carried out with solutions C and D (Table 2.6).  
Alternatively, proteins were analyzed using the Pierce silver stain kit for mass 
spectrometry (Sigma–Aldrich) according to the manufacturer‟s instructions. Digital gel 
images were captured using a universal hood II for Gel Doc XR (BioRad). 
 
Table 2.6: Composition of the solutions used for Coomassie staining 
 Solution A Solution B Solution C Solution D 
Coomassie R-250 0.05% (w/v) 0.05% (w/v) 0.002% (w/v) – 
Propan-2-ol 25%    (v/v) 10%    (v/v) – – 
Acetic acid 10%    (v /v) – 10% (v/v) 10% (v/v) 
 
2.2.4.4 Immunoblot analysis 
Protein bands were transferred from the SDS–polyacrylamide gel by electroblotting to a 
nitrocellulose membrane according to Towbin et al. (1979) for 35–40 min at 70–80 
mA/gel using the BioRad Mini Protean II tank blot device. SP–D was detected using a 
mouse monoclonal anti-human SP–D primary antibody directed against the C-terminal 
NCRD of SP–D (Hyb 246–04, Dianova) at a final concentration of 0.5 µg/ml. A 
polyclonal rabbit anti-mouse IgG/M–AP conjugate secondary antibody (Dako) was 
added at a final concentration of 4 µg/ml and detected using NBT/BCIP substrate 
(BioRad) using the protocol described in Table 2.7. 
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Table 2.7: Immunoblot protocol 
 
 
AP buffer (pH 9.6) 
 
Tris–HCl pH 9.6 100 mM 
NaCl 100 mM 
MgCl2    5 mM 
 
20x TBS buffer (pH 7.4) 
 
Tris–base      200 mM 
NaCl 2800 mM 
  
2.2.4.5  Enzyme linked immunosorbent assay  
To determine the concentration of human SP–D in crude extracts and elution fractions 
after purification (2.2.5.2, 2.2.5.3), the enzyme linked immunosorbent assay (ELISA) 
protocol outlined in Table 2.8 was used. Briefly, 96-well PVC ELISA plates (Greiner 
Bio–One) were coated with F(abʹ)2 rabbit anti-human SP–D (kindly provided by Dr. 
Grith Sorensen,  Institute of Molecular Medicine, University of Southern Denmark) at a 
final concentration of 1 µg/ml. Samples and standards were added as two-fold serial 
dilutions starting with a dilution factor of 1:100 in 1x TBS. Recombinant human SP–D 
from mouse myeloma cell line NS0 (R&D Systems) was used as the standard at a final 
concentration of 50 ng/ml. Bound SP–D was detected with a biotinylated monoclonal 
anti-human SP–D antibody (Hyb 246–04, Dianova) at final concentration of 0.5 µg/ml 
and the signal was revealed by adding pNPP substrate (Sigma–Aldrich). The plates were 
analyzed at 405 nm in an ELISA reader (Synergy HT from Bio–Tek).   
Step Concentration              Time [min] 
Block 5% (w/v) milk powder in 1x TBS   60  
Wash 3x with 1x TBS plus 5 mM CaCl2 and 
0.05% (v/v) Tween-20  
– 
Primary antibody 
 
1 mg/ml diluted 1:2000 in 1x TBS 60  
Wash 3x with 1x TBS plus 5 mM CaCl2 and 
0.05% (v/v) Tween-20  
– 
Secondary antibody 
 
1 mg/ml diluted 1:250 in 1x TBS 60  
Wash 3x with 1x TBS  plus 5 mM CaCl2 and 
0.05% (v/v) Tween-20  
– 
 
Development  
 
NBT/BCIP in AP buffer 
 
1–10 
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Table 2.8: ELISA protocol 
The assay was performed at room temperature and volumes are presented in µl/well. 
(*) in shaking platform 
 
Sodium carbonate buffer (pH 9.6) 
                        
Na2CO3        15 mM 
NaHCO3 34.9 mM 
SP buffer (pH 9.8) 
 
Diethanolamine 100 mM 
Na2HCO3    35 mM   
MgCl2 1 mM 
  
Step Volume  Concentration Time [min]  
Coating 100 1 mg/ml of F(abʹ)2 rabbit anti-human SP–D 
diluted 1:1000 in sodium carbonate buffer 
60 
(*)
 
 
Block 200 2% (w/v) BSA in 1x TBS 60 
Wash 200 3x with 1x TBS  + 5 mM CaCl2 and 0.05% 
(v/v) Tween-20 
– 
Sample  100 Variable  60 
Wash 200 3x with 1x TBS + 5 mM CaCl2 and 0.05% 
(v/v) Tween-20 
– 
Detecting 
antibody 
 
100 
 
1 mg/ml biotin-labeled monoclonal anti-
human hSP–D diluted 1:2000 in 1x TBS + 
5 mM CaCl2 and 0.05% (v/v) Tween-20  
 
60
 (*) 
 
Wash 200 3x with 1x TBS  + 5 mM CaCl2 and 0.05% 
(v/v) Tween-20 
– 
Streptavidin–AP 100 1 mg/ml diluted 1:1000 in 3x with 1x TBS 
+ 5 mM CaCl2 and 0.05% (v/v) Tween-20 
60 
 
Wash 
 
200 
 
3x with 1x TBS  + 5 mM CaCl2 and 0.05% 
(v/v) Tween-20  
 
– 
 
Development 
 
100 
 
pNPP in SP buffer  
 
< 30 
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 Chromatography methods 2.2.5
2.2.5.1 N-acetylmannosamine affinity chromatography using the ÄktaExplorer 10 
chromatography system 
The ÄktaExplorer 10 chromatography system (GE Healthcare) was used to find the best 
flow rate for the purification of untagged rhSP–D variants from tobacco leaves by 
N-acetylmannosamine chromatography (ManNAc) according to Sorensen et al. (2009). 
N-acetylmannosamine (Sigma–Aldrich) was immobilized on Sepharose CL–4B (GE 
Healthcare) using divinylsulfone-mediated covalent crosslinking. Then 500 µl of 
ManNAc resin was loaded onto a 50-ml Superloop (GE Healthcare), which was 
equilibrated with 1x PBS at 1 ml/min. The tobacco leaves were processed (2.2.4.1) and 
the filtered protein extract was diluted 2x in 1x TBS before loading onto the column. 
The column was washed with six column volumes (CV) of wash buffer and six CV of 
elution buffer at 0.1 ml/min. A gradient elution of 0.6 CV was applied. Finally, the 
purified fractions were dialyzed overnight at 4°C against 1x TBS containing 5 mM 
calcium chloride and 0.05% (v/v) Emulphogene® (Sigma–Aldrich). 
2.2.5.2 N-acetylmannosamine affinity chromatography using gravity flow 
ManNAc-coupled Sepharose resin was packed onto a gravity flow column (GE 
Healthcare) and equilibrated with 1x TBS. Protein was extracted from tobacco leaves 
(2.2.4.1) and the filtered protein extract was loaded onto the column and washed with 
ten CV of wash buffer containing 1 M NaCl to remove the nonspecific binding proteins. 
The untagged rhSP–D variants were eluted by gravity flow using five CV of elution 
buffer. Finally, the purified fractions were dialyzed overnight at 4°C against 1x TBS 
containing 5 mM calcium chloride and 0.05% (v/v) Emulphogene® (Sigma–Aldrich). 
 
Wash buffer 
 
CaCl2 5 mM 
Emulphogen® 0.05% (v/v) 
In 1x TBS (pH 7.4) 
Elution buffer 
 
MnCl2 100 mM 
Emulphogen® 0.05% (v/v) 
In 1x TBS (pH 7.4) 
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Emulphogen®  = polyoxyethylene-10 tridecyl ether from Sigma–Aldrich.  
All solutions were filtered using sterile 0.2-µm Whatman filters. 
 
2.2.5.3 Immobilized metal ion affinity chromatography   
His6-tagged rhSP–D variants were purified by immobilized metal ion affinity 
chromatography (IMAC). NTA agarose (Macharey–Nagel) and Chelating Sepharose 
Fast Flow (GE Healthcare) were packed into disposable plastic columns (GE 
Healthcare) and equilibrated with 1x PBS. The resins were then charged with 0.5 CV of 
0.2 M Ni
2+ 
or
 
Cu
2+
 according to the manufacturer‟s instructions. Proteins were extracted 
from tobacco leaves (2.2.4.1) and the filtered protein extract was loaded onto the 
column and then washed by adding 10 CV of wash buffer. His6-tagged rhSP–D variants 
were eluted using five CV of elution buffer. The column was regenerated with 10 CV of 
stripping buffer to remove the ions present on the resins to elute the remaining bound 
proteins. All elution fractions were dialyzed overnight at 4°C against 1x PBS.  
 
Wash buffer 
  
1x PBS (pH 7.4)   
 
Elution buffer 
 
Imidazole 500 mM 
In 1x PBS (pH 7.4) 
Stripping buffer 
 
NaCl 500 mM 
EDTA 50 mM 
NaPO4 20 mM 
 
The solutions were filtered using sterile 0.2-µm Whatman filters. 
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 Functionality assays 2.2.6
2.2.6.1  Competitive ELISA 
The ability of the different rhSP–D variants to bind to yeast mannan in competition with 
other saccharides was determined by competitive ELISA as described by Sorensen et al. 
(2005) using the protocol in Table 2.9. Briefly, 96–well PVC ELISA plates (Greiner 
Bio–One) were coated with Saccharomyces cerevisiae purified mannan (Sigma–
Aldrich). The assay was performed using 0–500 mM N-acetyl-D-mannosamine, 
maltose, glucose and galactose (Sigma–Aldrich) as competitors in the presence of 5 mM 
calcium chloride. Dilutions of the saccharides (50 µl volume) were added in duplicate to 
each well. A negative control (1x TBS plus 5 mM calcium chloride and 0.05% (v/v) 
Tween-20 without saccharides) was also included. Purified rhSP–D at a final 
concentration of 2 µg/ml (50 µl volume) was then added in duplicate and bound rhSP–D 
was detected by adding a biotin-labeled mouse monoclonal anti-human SP–D antibody 
(Hyb 246–04B, Dianova). The signal was developed by adding pNPP substrate (Sigma–
Aldrich) and the plates were analyzed at 405 nm in a Synergy HT ELISA reader (Bio–
Tek). 
Table 2.9: Competitive ELISA protocol 
The assay was performed at room temperature and volumes are presented in µl/well. 
(*) in shaking platform 
Step  Volume  Concentration Time [min]  
Coating 100 1 µl/ml mannan in sodium carbonate 
buffer 
120 
Block 200 2% (w/v) BSA in 1x TBS 60 
Wash 200 3x with 1x TBS  + 5 mM CaCl2 and 0.05% 
(v/v) Tween-20 
– 
Sample  100 500 mM saccharides + 2 µg/ml purified 
protein   
60 
Wash 200 3x with 1x TBS + 5 mM CaCl2 and 0.05% 
(v/v) Tween-20 
– 
Detecting 
antibody 
 
100 
 
1 mg/ml biotin-labeled monoclonal anti-
human hSP–D diluted 1:2000 in 1x TBS + 
5 mM CaCl2 and 0.05% (v/v) Tween-20  
 
60
 (*) 
 
Wash 200 3x with 1x TBS  + 5 mM CaCl2 and 0.05% 
(v/v) Tween-20 
– 
Streptavidin–AP 100 1 mg/ml diluted 1:1000 in 3x with 1x TBS 
+ 5 mM CaCl2 and 0.05% (v/v) Tween-20 
60 
 
Wash 
 
200 
 
3x with 1x TBS  + 5 mM CaCl2 and 0.05% 
(v/v) Tween-20  
 
– 
 
Development 
 
100 
 
pNPP in SP buffer  
 
< 30 
 Materials and methods  
 
35 
 
2.2.6.2  Bacterial agglutination assay 
The ability of different rhSP–D variants to bind and agglutinate bacteria was determined 
according to Kuan et al. (1992) and Craig-Barnes et al. (2010) with minor modifications 
(Table 2.10). E. coli DH5α cells (2.1.8) were grown overnight in LB at 160 rpm and 
37°C. Aggregation was assessed by measuring the increase of turbidity after the 
addition of 2 µg/ml purified rhSP–D in presence of 4 mM of calcium chloride, with 2 
µg/ml of purified rhSP–D from mice myeloma cells (R&D Systems) as a positive 
control, and 100 mM maltose (Sigma–Aldrich) and DsRed from plant crude extract as 
negative controls. A blank E. coli suspension without the purified rhSP–D was also 
included. The samples were placed on flat-bottom polystyrene microtiter plates (Greiner 
Bio–One) in a total volume of 100 μl per well and the absorbance (OD600) was 
measured at 5-min intervals for 60 min in a Synergy HT spectrophotometer (Bio–Tek).  
 
Table 2.10: Bacterial agglutination protocol 
 
Step Description  Time [min] 
Day 1   
E. coli growth 
 
5 ml LB without antibiotics + 50 
µl DH5α cells from glycerol 
stock 
overnight 
(160 rpm, 37°C) 
Day 2   
E. coli growth 
 
50 ml fresh LB + overnight 
bacterial suspension 
240 
(160 rpm, 37°C) 
Optical density 
measurement 
OD600 = 1  
Centrifugation  3x at 4000 x g 5 
Pellet  
resuspension   
3x in 1x TBS – 
Adjust optical density OD600 = 1 in sodium carbonate 
buffer 
– 
Sample Sample addition to microtiter 
plates  
– 
Time course 
measurement 
OD600 measured at 5-min 
intervals  
60 
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 Results 3
The production of rhSP–D variants using heterologous expression platforms such as 
mammalian cells and E. coli has developed significantly over the last few decades and 
represents a promising approach to support surfactant products that are already available 
on the market, particularly for the treatment of RDS. However, the global demand will 
grow when rhSP–D is approved for infectious and inflammatory lung diseases such as 
asthma and cystic fibrosis, and current production systems will not be able to produce 
sufficient quantities of the protein (Salgado et al. 2014). Plant-based expression was 
therefore considered as an alternative to microbial and mammalian cells for the 
production of rhSP–D to ensure that the production capacity for this protein meets the 
growing global demand. Accordingly, this PhD thesis is structured in two parts: 
 
1. Establishment of a plant-based expression platform for the high-level production of 
rhSP–D (3.1) 
2. Characterization of rhSP–D variants in terms of C-type lectin activity (3.2) 
 
3.1 Establishment of a plant-based expression platform for the 
high-level production of rhSP–D 
 
The production of high levels of rhSP–D in plants requires the establishment of a 
suitable expression system (3.1.1) as well as the development of an efficient strategy for 
isolation and purification (3.1.2). This chapter describes the stepwise development of a 
production platform based on tobacco plants. 
 Establishment of a plant-based expression system 3.1.1
The first step towards the production of rhSP–D in tobacco plants is the establishment 
of an efficient expression system that enables the production of functional, fully 
assembled hSP–D. This chapter describes the development of expression constructs for 
diverse forms of rhSP–D: full-size hSP–D, hNCRD (comprising the neck and CRD 
domains) and an hNCRD–DsRed fusion protein (3.1.1.1). The expression constructs 
were compared in terms of protein accumulation levels in the apoplast and cytosol 
following transient expression (3.1.1.2). The targeting of rhSP–D variants to the 
apoplast was achieved by adding an N-terminal signal peptide and the intracellular 
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cytosolic versions were generated by omitting the signal peptide. The best-performing 
constructs in terms of protein accumulation were selected for stable transformation in 
tobacco plants (3.1.1.3). 
3.1.1.1  Expression construct design and cloning 
Thirteen constructs were designed containing cDNAs encoding full-size hSP–D, 
hNCRD and the hNCRD–DsRed fusion protein. This began with the design of eight 
building blocks (I–VIII) in silico using: 1) the full-size hSP–D sequence (GenBank 
AAB59450.1) as a template, 2) the Tobacco etch virus (TEV) 5'-UTR from vector 
pTRApt (Annex, Figure 7.1), 3) the His6 tag sequence at either the N-terminal or C-
terminal of each cDNA, and 4) a signal peptide to target the rhSP–D variants to the 
apoplast. Building blocks without the His6 tag sequences and/or the signal peptide were 
also designed. The blocks were then combined to generate 10 cDNA sequences that 
were synthetized and inserted into the vector pUC by GenScript®, and introduced into 
E. coli competent cells by heat shock transformation (2.2.2.1). This development 
scheme is shown in Figure 3.1               
 
                 Blocks generation                                Blocks combination                         
                                                                   
                                                                    V–I 
 
                                                                    VII–I    
 
 Block I                                                       V–II 
 
 Block II                                                      V–III 
 
 Block III                                                     VII–III 
 
 Block IV                                                     V–IV    
 
 Block V                                                      VI–I  
 
 Block VI                                                     VIII–I 
 
N N N 
N N N N 
N N N N 
N N N N N 
N N N N N 
N N 
N N N 
SP H  Full-size hSP–D TL 
TL 
TL 
TL 
TL 
TL 
SP 
SP 
SP 
ND 
ND 
ND 
Full-size hSP–D 
Full-size hSP–D 
CRD 
CRD 
CRD 
H  
H  
H  
N N N N 
Full-size hSP–D 
ND CRD NCD CD 5’3’ Full-size hSP–D TL SP 
BspHI 
BspHI 
BspHI 
BspHI 
BspHI 
BspHI 
BspHI EcoRI 
EcoRI 
EcoRI 
EcoRI 
EcoRI 
EcoRI 
EcoRI 
BamHI 
BamHI 
BamHI 
BamHI 
BamHI 
BamHI 
BamHI 
NcoI 
NcoI 
NcoI 
NcoI 
NcoI 
NcoI 
BspHI 
BspHI 
BspHI 
BspHI 
BspHI 
BamHI 
BamHI 
BamHI 
EcoRI 
EcoRI 
NcoI 
N 
N N 
N N 
N 
N N 
N 
N 
N 
N N N N 
BspHI EcoRI BamHI NcoI BamHI 
TL H  Full-size hSP–D SP Full-size hSP–D 
H  Full-size hSP–D 
CRD ND 
H CRD ND 
TL SP
TL 
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  VI–III 
   
    VIII–III 
 
Figure 3.1: Generation and combination of building blocks for plant expression constructs 
NCD: cDNA encoding the non-collagenous domain of hSP–D, CD: cDNA encoding the collagenous 
domain of hSP–D, ND: cDNA encoding the neck domain of hSP–D, CRD: cDNA encoding the 
carbohydrate recognition domain of hSP–D, TL: Tobacco etch virus (TEV) 5ʹ-UTR from pTRApt, SP: N-
terminal signal peptide, H: histidine tag. Not drawn to scale. 
 
After plasmid isolation (2.2.1.4) the synthetic sequences were removed from pUC by 
digestion with EcoRI and BamHI and ligated into vector pTRApt (Figure 3.2). This is an 
optimized plant expression vector containing the double enhanced Cauliflower mosaic 
virus (CaMV) P35SS promoter, the TEV 5ʹ-UTR, the CaMV pA35S polyadenylation 
site, scaffold attachment regions (SARs) to improve gene expression, the β-lactamase 
gene (bla) to confer ampicillin resistance in E. coli and carbenicillin resistance in A. 
tumefaciens and the bialaphos resistance gene (pat) as a selectable marker for transgenic 
plants (Annex, Figure 7.1). 
To generate expression constructs SPD9 and SPD12, which were not contemplated in 
the original in silico design, the signal peptide from constructs SPD3 and SPD6 was 
removed using EcoRI and BspHI. In the DsRed–NCRD construct, it was necessary to 
fuse the cDNA encoding the red fluorescent protein from Discosoma sp. to the hSP–D 
sequence using construct SPD5 as the template. The final expression constructs, with 
and without a signal peptide targeting the rhSP–D variants to the apoplast rather than 
the default cytosol pathway, were then introduced into E. coli. For each transformation 
event, a positive clone was chosen after plasmid digestion (2.2.1.3), and the correct 
insertion into the pTRApt vector was verified by sequencing (2.2.1.7). The plasmids 
were then transferred into A. tumefaciens strain GV3101 by electroporation (2.2.2.4).  
 
 
 
 
 
 
 
N N N 
N N 
N N N 
N N N N 
TL ND CRD 
ND CRD 
Block VII 
Block VIII 
TL 
TL 
SP H  
H  
BspHI 
BspHI EcoRI 
EcoRI 
BamHI 
BamHI 
BspHI 
BspHI 
EcoRI 
EcoRI 
NcoI 
H  TL 
Results  
 
39 
 
 
 
 
pTRA–SPD–apo (SPD1) 
pTRA–his–SPD–apo (SPD2)  
pTRA–SPD–his–apo (SPD3)  
pTRA–NCRD–apo (SPD4) 
pTRA–his–NCRD–apo (SPD5)  
pTRA–NCRD–his–apo (SPD6) 
pTRA–SP–D–cyto (SPD7)  
pTRA–his–SP–D–cyto (SPD8)  
pTRA–SP–D–his–cyto (SPD9)  
pTRA–NCRD–cyto (SPD10)  
pTRA–his–NCRD–cyto (SPD11) 
pTRA–NCRD–his–cyto (SPD12)  
pTRA–his–DsRed–NCRD–apo (DsRed–NCRD) 
Figure 3.2: T-DNA region of the 13 pTRApt plant expression vectors containing gene cassettes 
targeting rhSP–D variants to the apoplast or cytosol  
LB: left border of the T-DNA, RB: right border of the T-DNA, Pnos and pAnos: promoter and terminator 
of the nopaline synthase gene, pat: bialaphos/phosphinothricin resistance gene, SAR: scaffold attachment 
region, P: 35S promoter with duplicated enhancer, pA: terminator of the CaMV 35S gene, TL: TEV 5' 
UTR, SP: N-terminal signal peptide, H: histidine tag sequence, ND: cDNA encoding the neck domain of 
hSP–D, CRD: cDNA encoding the carbohydrate recognition domain of hSP–D, DsRed: cDNA encoding 
the red fluorescent protein from Discosoma sp. Not drawn to scale. 
 
3.1.1.2 Comparison of recombinant protein levels in the apoplast and cytosol 
The best targeting strategy resulting in the highest yields of full-size hSP–D, hNCRD 
and the hNCRD–DsRed fusion protein in plants (3.1.1.1) was determined by transient 
expression (2.2.2.4, 2.2.2.5) using the leaf disc infiltration method (2.2.3.3). Five days 
post-infiltration (dpi) total soluble proteins were extracted and analyzed by ELISA and 
immunoblot. DsRed transiently expressed in tobacco leaves was used as a negative 
control. The results are shown in Figure 3.3 
N
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Figure 3.3: Comparison of rhSP–D yields and detection by immunoblot after transient expression 
in tobacco leaves  
Accumulation of (A) full-size hSP–D and (B) hNCRD. Total soluble proteins were extracted by grinding 
tobacco leaf tissue in two volumes of extraction buffer (2.2.4.1). The values were determined by ELISA 
(2.2.4.5) with the F(ab')2 rabbit anti-human SP–D capture antibody and biotin-labeled monoclonal anti-
human SP–D detection antibody.  Recombinant hSP–D from mouse myeloma cell line (R&D Systems) 
was used as a standard and DsRed transiently expressed in tobacco leaves was used as negative control. 
Error bars represent the standard deviations from technical triplicates. SPD1/7: secreted and non-secreted 
untagged full-size hSP–D, SPD2/8: secreted and non-secreted full-size hSP–D with N-terminal His6 tag, 
SPD3/9: secreted and non-secreted full-size hSP–D with C-terminal His6 tag, SPD4/10: secreted and non-
secreted untagged hNCRD, SPD5/11: secreted and non-secreted hNCRD with N-terminal His6 tag, 
SPD6/12: secreted and non-secreted hNCRD with C-terminal His6 tag.(C, D and E) Immunoblot analysis 
of secreted full-size hSP–D, hNCRD and the hNCRD–DsRed fusion protein. A 15-μl protein extract 
(2.2.4.1) was separated by 12% (w/v) SDS–PAGE under non-reducing conditions and blotted onto a 
nitrocellulose membrane. Immunoblot analysis (2.2.4.4) was carried out using monoclonal anti-human 
SP–D from mice followed by polyclonal rabbit anti–mouse Ig–AP conjugate.Development time: 1–10 
min. M: pre-stained protein 1-kb marker (Fermentas), (+) positive control: rhSP–D from mouse myeloma 
cell line (~5 µg, R&D Systems), (–) negative control: soluble proteins from wild-type plant crude extract, 
DsRed–NCRD: secreted His6-tagged hNCRD–DsRed fusion protein. 
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The results of the ELISA (Figure 3.3A and B) show that full-size hSP–D and hNCRD 
accumulate to higher levels when secreted to the apoplast, whereas the cytosolic forms 
are not detected. The secreted untagged full-size hSP–D (construct SPD1) accumulated 
to the highest levels (~180 mg/kg fresh leaf weight, FLW), followed by the full-size 
hSP–D with N-terminal His6 tag and the untagged hNCRD (constructs SPD2 and SPD4, 
respectively) each with levels of ~50 mg/kg FLW. However, the calculated yields in the 
ELISA do not correspond to the strong band of the positive control (rhSP–D from a 
murine myeloma cell line) on the immunoblot (Figure 3.3C to E). This discrepancy 
suggests that the protein concentration is overestimated by the ELISA procedure.  
Because the cytosolic rhSP–D variants were not detected, only the secreted forms were 
analyzed by immunoblot. Under non-reducing conditions, full-size hSP–D with and 
without the His6 tag (constructs SPD1–SPD3, Figure 3.3C) yielded an upper band with 
an apparent molecular weight of ~170 kDa and lower bands of ~80 and ~40 kDa which 
indicate the presence of trimers, dimers and monomers of full–size hSP–D (Sorensen et 
al. 2009; Oberley et al. 2004). Similarly, the secreted tagged and untagged hNCRD 
forms (constructs SPD4–SPD6, Figure 3.3B) appeared mainly as a ~15–18 kDa trimer, 
as previously reported for human and rat NCRD (Crouch et al. 2005; Madan et al. 2001; 
Kishore et al. 1996). Immunoblot analysis of the secreted hNCRD–DsRed fusion 
protein (Figure 3.3E) revealed a band of ~170 kDa, which is larger than the combined 
sizes of hNCRD (~16 kDa) and monomeric DsRed (~26 kDa), suggesting that this 
upper band could correspond to the tetrameric fusion protein of ~168 kDa generated by 
the self-assembly of DsRed [4 x (16 + 26)] (Baird et al. 2000).  The lower band of ~40 
kDa may indicate the monomeric hNCRD–DsRed fusion protein and the band of ~16 
kDa could correspond to partial degradation by endogenous proteases in the apoplast of 
tobacco leaves.   
3.1.1.3 Stable expression of rhSP–D variants in tobacco plants 
Based on the high yields obtained by transient expression, the following constructs were 
chosen for stable transformation: SPD1 (encoding the untagged full-size hSP–D), SPD2 
(full-size hSP–D with N-terminal His6 tag), SPD4 (encoding the untagged hNCRD) and 
SPD5 (hNCRD with N-terminal His6 tag). The fusion protein was not selected because 
DsRed is not yet approved by the FDA for pharmaceutical use, even though the 
transient expression experiments confirmed that is supports the assembly of trimeric 
hNCRD.  
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For each construct, 25 transgenic plants were regenerated and the accumulation of each 
rhSP–D variant in the leaves of T0 plants was screened by immunoblot (data not 
shown). After self-pollination, T1 seeds from 3–5 of the highest expressing plants for 
each construct were tested for germination on agar plates with bialaphos, and 10 
resistant T1 plants per line were transferred to soil and grown in the greenhouse 
(2.2.3.1). These plants were screened for the accumulation of rhSP–D variants by 
ELISA. The highest yields were achieved for the full-size hSP–D with N-terminal His6 
tag (up to 60 mg/kg FLW) and for the untagged hNCRD (40 mg/kg FLW). In the T2 
generation, the highest yields were 80 mg/kg FLW for full-size hSP–D with N-terminal 
His6 tag and 60 mg/kg FLW for untagged hNCRD. The untagged full-size hSP–D and 
hNCRD with an N-terminal His6 tag showed consistent yields of 20–30 mg/kg FLW in 
the T1 and T2 generations (Table 3.1). Interestingly, the yield of the untagged full-size 
hSP–D was increased by six-fold from the T2 to the T3 generation, reaching ~250–300 
mg/kg FLW. However, this may reflect an overestimation of the protein concentration 
by ELISA due to contaminants that interfered with quantification. Constructs SPD2, 
SPD4 and SPD5 have yet to be tested in the T3 generation. 
 
Table 3.1: Accumulation of recombinant full-size hSP–D and hNCRD in transgenic tobacco plants  
The accumulation levels (mg/kg FLW) were determined by ELISA (2.2.4.5) using F(ab')2 rabbit anti-
human SP–D and biotin-labeled monoclonal anti-human hSP–D antibodies and purified rhSP–D from a 
murine myeloma cell line (R & D Systems) as a standard.  
Description Construct T1 generation T2 generation  T3 generation  
Untagged full-
size hSP–D  
SPD1 20–50 30–50 250–300 
Full-size hSP–D 
with N-terminal 
His6 tag 
SPD2 20–60  20–80 – 
Untagged 
hNCRD  
SPD4 10–40  30–60 – 
hNCRD with N-
terminal His6 tag 
SPD5 15–30 15–30 – 
 
 Isolation of rhSP–D  variants from tobacco leaves 3.1.2
The functionality of untagged and His6-tagged rhSP–D variants produced by transient 
expression in tobacco was tested using purified protein obtained by ManNAc 
chromatography (3.1.2.1) or IMAC (3.1.2.2) respectively. The purified rhSP–D variants 
were then analyzed to determine their C-type lectin activity (3.2). 
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3.1.2.1 N-acetylmannosamine affinity chromatography 
The optimal flow rate for the purification of the untagged rhSP–D variants by ManNAc 
chromatography was established by screening crude extracts from tobacco leaves 
transiently expressing the untagged full-size hSP-D. The ÄktaExplorer 10 system 
(2.2.5.1) was set up at flow rates of 30, 75, 150 and 300 cm/h.  As shown in Figure 3.4, 
the higher flow rates reduced the recovery of the target protein. Therefore, the lowest 
flow rate was used for further ManNAc purification steps. 
                     
Figure 3.4: Sample application screening with untagged full-size hSP–D from crude plant extracts 
after transient expression  
After loading the ÄktaExplorer 10 chromatography system superloop with clarified plant extracts and 
washing with TBS containing 5 mM of calcium chloride (2.2.5.1) the untagged full-size hSP–D was 
eluted at a flow rate of 30 cm/h.  
 
Having determined that a low flow rate is important for the elution of the untagged full-
size hSP–D during ManNAc chromatography, the ÄktaExplorer 10 system was 
discarded because the low flow rate combined with the high risk of resin fouling due to 
the accumulation of tobacco phenolics and alkaloids could encourage the column to 
collapse and inhibit purification. To avoid this issue while maintaining the necessary 
low flow rate during purification, a bench-scale system was set up using gravity flow 
columns packed with N-acetylmannosamine coupled to Sepharose resin (2.2.5.2). Three 
tobacco leaves were infiltrated with recombinant A. tumefaciens (2.2.3.2) carrying 
SPD1 or SPD4 (2.2.3.1). Five days post-infiltration, the soluble proteins were extracted 
to purify the untagged full-size hSP–D and hNCRD by ManNAc chromatography 
(2.2.5.2). The concentrations of purified proteins were determined by ELISA (2.2.4.5). 
The results are shown in Figure 3.5. 
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              A                                       B                                                   
                                                            
              C                                       D  
                                    
Figure 3.5: Detection of untagged full-size hSP–D and hNCRD after ManNAc chromatography 
(A) Coomassie-stained gel and (B) immunoblot analysis of partially-purified untagged full-size hSP–D 
after transient expression. (C) Coomassie-stained gel and (D) immunoblot analysis of partially-purified 
untagged hNCRD after transient expression. Lanes were loaded with 15 μl of load (L, clarified extract 
from tobacco leaves), flow through (F) from ManNAc resin, wash (W), and elution (E) fractions. The 
fractions were separated by 12% (w/v) by SDS–PAGE under non-reducing conditions. After 
immunoblotting (2.2.4.4) SP–D was detected using a mouse monoclonal anti-human SP–D primary 
antibody, a polyclonal rabbit anti-mouse Ig–AP secondary antibody conjugate and NBT/BCIP substrate. 
Development time: 1–10 min. M: pre-stained protein 1-kb marker (Fermentas), (+) positive control: 
recombinant hSP–D from a murine myeloma cell line (~5 µg, R&D Systems), (–) negative control: 
DsRed transiently expressed in tobacco plants. This sample was obtained after loading the clarified 
protein extract onto the ManNAc column. The black arrows indicate the molecular sizes of hNCRD and 
full-size hSP–D. 
 
As shown in Figure 3.5, after loading the protein extract and washing with TBS in the 
presence of calcium, the bound proteins were eluted with manganese chloride as 
previously described by Sorensen et al. (2009). The concentrations of purified full-size 
hSP–D (~24 mg/l) and hNCRD (~34 mg/l) were determined by ELISA (2.2.4.5). 
However, the recovery of each variant was poor (9.7% for untagged full-size hSP–D 
and 14% for untagged hNCRD). The target proteins could not be detected by Coomassie 
staining (Figure 3.5A and C) so their purity could not be calculated. ManNAc therefore 
appears to achieve only partial protein purification. Immunoblot analysis of the 
ManNAc fractions (Figure 3.5B) revealed differences in molecular weight between 
recombinant full-size hSP–D from tobacco leaves and murine myeloma cell line 
positive control. The latter shows bands that correspond to the size of the monomer (40 
kDa), dimer (80 kDa) and trimer (170 kDa) of full-size hSP–D, whereas the tobacco 
products were smaller (~35, ~70 kDa and ~170 kDa) and there was an additional ~46 
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kDa that may represent a full-size hSP–D monomer as previously detected in serum and 
bronchoalveolar lavage fluid (Leth–Larsen et al. 2005; Mason et al. 1998). The hNCRD 
protein migrated with an apparent molecular weight of ~15–16 kDa (Figure 3.5D) as 
previously described for trimeric NCRD in E. coli (Madan et al. 2001; Crouch et al. 
2005). 
3.1.2.2 Immobilized metal ion affinity chromatography  
To purify the His6-tagged rhSP–D variants, three tobacco leaves were infiltrated as 
above (2.2.3.2) with A. tumefaciens previously transformed with constructs SPD2, 
SPD3, SPD5, SPD6 or the NCRD–DsRed fusion construct (2.2.2.4, 2.2.2.5). Five days 
post-infiltration, soluble proteins were extracted and the His6-tagged hSP–D variants 
were purified by IMAC (2.2.5.3). Purified proteins were visualized by immunoblot and 
their concentrations were determined by ELISA. The results are shown in Figures 3.6 
and 3.7 and in Table 3.2. 
 
                 
 
                 
Figure 3.6: Immunoblot analysis of His6-tagged full-size hSP–D and hNCRD purified by IMAC  
After transient expression in tobacco (2.2.3.2), His6-tagged rhSP–D variants were purified by IMAC-Ni
2+ 
(2.2.5.3).
 
(A) Full-size hSP–D with N-terminal His6 tag, (B) full-size hSP–D with C-terminal His6 tag, (C) 
hNCRD with N-terminal His6 tag and (D) hNCRD with C-terminal His6 tag. Lanes were loaded with 15 
μl of the load (L) and elution (E) fractions and separated by 12% (w/v) SDS–PAGE followed by 
immunoblotting under non-reducing conditions (2.2.4.4). SP–D was detected using a murine monoclonal 
anti-human SP–D primary antibody, a polyclonal rabbit anti-mouse Ig–AP secondary antibody conjugate 
and NBT/BCIP substrate. Development time: 1–10 min. M: pre-stained protein 1-kb marker (Fermentas), 
(+) positive control: recombinant hSP–D from a murine myeloma cell line (~5 µg, R&D Systems), (–) 
negative control: clarified wild-type plant crude extract. The black arrows indicate the molecular sizes of 
hNCRD and full-size hSP–D. 
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Table 3.2: Yield and recovery of tagged full-size hSP–D and hNCRD after NTA–Ni2+ IMAC  
Yields were determined by ELISA (2.2.4.5) using F(ab')2 rabbit anti-human SP–D and biotin-labeled 
monoclonal anti-human SP–D antibodies. Purified rhSP–D from a murine myeloma cell line (R&D 
Systems) was used as a standard.  
rhSP–D variants Protein amount (mg/l) Recovery (%) 
Full-size hSP–D with N-terminal His6 tag  16 0.8 
Full-size hSP–D with C-terminal His6 tag  2 0.7 
hNCRD with N-terminal His6 tag  27 9.5 
hNCRD with C-terminal His6 tag  10 13 
 
 
As shown in Figure 3.6A and B, the non-reducing conditions revealed bands with 
apparent molecular sizes representing the monomer (~37 kDa), dimer (~70 kDa) and 
trimer (~170 kDa) of full-size hSP–D plus the His6 tag. Similarly, hNCRD plus the His6 
tag yielded a band of ~15–16 kDa (Figure 3.6C and D) reminiscent of the trimeric 
NCRD expressed in E.coli (Madan et al. 2001; Crouch et al. 2005). The upper bands 
detected in both immunoblots (Figure 3.6C and D) may indicate the formation of 
aberrant disulfide bonds between CRDs.  
Although the His6-tagged rhSP–D forms could be purified by IMAC, no bands were 
detected by Coomassie staining (data not shown) so it was not possible to estimate the 
purity. The yield and recovery of the proteins were also poor (Table 3.2). Taking these 
results into account, only partial purification of the His6-tagged full-size hSP–D and 
hNCRD appears possible by IMAC. Even so, there was enough of each protein to 
complete the functional assays with the exception of the hNCRD–DsRed fusion protein, 
where an additional  IMAC–Cu2+ step was necessary after IMAC–Ni2+ based on the 
high affinity of DsRed for Cu
2+
 (Rahimi et al. 2007). This resulted in the purification of 
~20.5 mg/l of hNCRD–DsRed compared to ~3.5 mg/l achieved by IMAC–Ni2+. The 
elution fraction was analyzed by native electrophoresis and the hNCRD–DsRed fusion 
protein was represented by a ~170-kDa band as discussed above (3.1.1.2) (Figure 3.7A 
and B). The lower bands of ~42 may indicate the monomeric hNCRD–DsRed fusion 
protein and the bands of ~30 and 15 kDa could correspond to partial degradation by 
endogenous proteases in the apoplast of tobacco leaves.   
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                           A                                         B     
                  
Figure 3.7: SDS-PAGE of the hNCRD–DsRed fusion protein purified by IMAC followed by 
Coomassie staining and immunoblot analysis  
After transient expression in tobacco (2.2.3.2), the hNCRD–DsRed fusion protein was purified by IMAC– 
Cu
2+ 
(2.2.5.3).
 
(A) Immunoblot of hNCRD–DsRed purified by IMAC–Cu2+ (B) SDS-PAGE and 
Coomassie staining of purified hNCRD–DsRed (15 μl of the elution fraction, E). Immunoblotting under 
non-reducing conditions (2.2.4.4) was followed by detection using a murine monoclonal anti-human SP–
D primary antibody, a polyclonal rabbit anti-mouse Ig–AP secondary antibody conjugate and NBT/BCIP 
substrate.Development time: 1–10 min. M: pre-stained protein 1-kb marker (Fermentas), (+) positive 
control: recombinant hSP–D from a murine myeloma cell line (~5 µg, R&D Systems), (–) negative 
control: clarified wild-type plant crude extract. 
3.1.2.3 Detection of purified rhSP–D by silver staining  
As discussed above (3.1.2.1 and 3.1.2.2) none of the partially-purified rhSP–D variants 
could be detected by Coomassie staining. ManNAc purification was therefore carried 
out using extracts from T3 transgenic tobacco plants expressing untagged full-size hSP–
D with yields of 200–300 mg/kg FLW (3.1.1.3). Figure 3.8 shows the elution fraction of 
untagged full-size hSP–D analyzed by silver staining and immunoblotting. 
          
            A                                                     B 
                                                
Figure 3.8: Silver staining and immunoblot analysis of purified untagged full-size hSP–D from 
stably transformed tobacco plants  
Transgenic tobacco plants (2.2.3.4) expressing full-size rhSP–D were used to prepare crude leaf extracts 
which were purified by ManNAc chromatography (2.2.5.2). (A) Immunoblot analysis of purified 
fractions under reducing conditions (2.2.4.4). (B) Silver staining of purified fractions (2.2.4.3). Each lane 
was loaded with 15 μl of the elution fraction (E) and separated by 12% (w/v) by SDS–PAGE. After 
immunoblotting, SP–D was detected using a murine monoclonal anti-human SP–D primary antibody, a 
polyclonal rabbit anti-mouse Ig–AP secondary antibody conjugate and NBT/BCIP substrate. M: pre-
stained protein 1-kb marker (Fermentas), (+) positive control: rhSP–D from a murine myeloma cell line 
(~30 ng, R&D Systems), (–) negative control: clarified crude extract from wild-type tobacco plants. 
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After ManNAc chromatography, the yield of partially-purified untagged full-size hSP–
D from transgenic tobacco plants was ~500 mg/l as determined by ELISA. However, no 
bands were detected by Coomassie staining (data not shown), again suggesting that the 
ELISA protocol was overestimating the concentration, perhaps due to the presence of 
contaminants in the crude extract that affected the assay. A sensitive silver staining 
method was therefore used, revealing a major band with a molecular weight of ~15–16 
kDa on the stained gel and the immunoblot (Figure 3.8A and B). This band could 
indicate the presence of endogenous proteases in the apoplast that cleaved the N-
terminal and collagenous regions of the full-size hSP–D generating a final molecular 
weight resembling that of the trimeric neck and CRD domains (Madan et al. 2001). The 
discrepancy between the band intensity in the immunoblot of partially-purified untagged 
full-size hSP–D and the positive control (Figure 3.8A) confirmed that the ELISA-based 
quantification was unreliable.  
3.2 Characterization of rhSP–D variants for C-type lectin activity  
 
In order to test the functionality of the secreted full-size hSP–D, hNCRD and hNCRD–
DsRed fusion protein, they were analyzed by competitive ELISA and bacterial 
agglutination assays to measure their C–type lectin activity, i.e. their ability to bind to 
saccharides in the presence of calcium. The competitive ELISA (3.2.1) and bacterial 
agglutination assay (3.2.2) are described in sections 2.2.6.1 and 2.2.6.2. Finally a 
stability assay was carried out to determine the optimal thermal conditions for the 
storage of functional rhSP–D variants (3.2.3). 
 Competitive ELISA 3.2.1
A saccharide inhibition assay was carried out using a competitive ELISA protocol 
(2.2.6.1) to determine the ability of the different rhSP–D variants to bind yeast mannan 
in the presence of other saccharides (Sorensen et al. 2005). This assay was carried out 
using 2 µg/ml of each partially-purified rhSP–D variant obtained by ManNAc 
chromatography (3.1.2.1) or IMAC (3.1.2.2). The inhibition of rhSP–D binding was 
estimated by determining the corresponding IC50 values as shown in Table 3.3. The 
inhibition curves for the assays are shown in the Figure 3.9. 
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Table 3. 3: Competitive ELISAs with partially-purified rhSP–D variants 
The IC50 values (concentration achieving 50% inhibition of protein binding) were determined by the 
inhibition of rhSP–D binding to mannan-coated plates in the presence of other saccharides. Three 
independent assays were carried out using 0–500 mM of each saccharide in the presence of 5 mM 
calcium. Differences between the mean absorbance values of N-acetylmannosamine (ManNAc) versus 
the other saccharides were compared using a two-tailed, unpaired t test, with p < 0.05 considered 
significant (*) p < 0.05, (**) p < 0.005, (ns) not significant.  
Saccharides (IC50 mM) 
rhSP–D variants ManNAc Maltose Glucose Galactose 
Untagged full-size hSP–D 1.7 4.5 (*) 8.5 (**) 23.1 (**) 
Full-size hSP–D with N-terminal His6 tag  6.8 6.2 (*) 14.3 (*) 22.2 (**) 
Untagged hNCRD 2.7 4.3 (ns) 7.5 (ns) 10  (ns) 
hNCRD with N-terminal His6 tag  4.1 6.2 (ns) 9.7 (ns) 31.4 (ns) 
hNCRD–DsRed fusion with N-terminal His6 tag  8.8 26 (*) 43 (*) 46.6 (**) 
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Figure 3. 9: Inhibitions curves for three independent competitive ELISA experiments 
The untagged and His6-tagged rhSP–D variants produced by transient expression were incubated in 
mannan-coated plates in the presence of selected monosaccharides and disaccharides for 1 h at room 
temperature (2.2.6.1). Data are presented as percentage values compared to the control. Representative 
inhibition curves are shown for: (A) Untagged full-size hSP–D; (B) Untagged hNCRD; (C) Full-size 
hSP–D with N-terminal His6 tag; (D) hNCRD with with N-terminal His6 tag and (E) hNCRD–DsRed 
fusion protein. Orange: N–acetylmannosamine; blue: maltose; red: glucose; green: galactose. Negative 
control: purified DsRed, which demostrated no affinity for any sugar (0% binding). The IC50 (mM) data 
for these experiments are compiled in Table 3.3. Error bars represent the standard deviations from three 
independent experiments (n= 3). 
 
As shown in Table 3.3, the saccharide binding preference of the rhSP–D variants was 
assessed by the inhibition of mannan binding (Sorensen et al. 2005; Crouch et al. 2005). 
N-acetylmannosamine was the preferred binding substrate for all of the secreted rhSP–D 
variants. The order of binding preference was N-acetylmannosamine > maltose > 
glucose > galactose. However, only N-terminal His6-tagged and untagged full-size hSP–
D and hNCRD–DsRed fusion protein showed significant differences (p < 0.05) in 
preference between N-acetylmannosamine and maltose or glucose. The fusion protein 
also showed higher IC50 values than the other rhSP–D variants reflecting its high 
oligomerization state. None of the small differences among the saccharides in terms of 
binding preference were statistically significant, which may indicate that the CRDs bind 
weakly to the saccharides due to incorrect protein folding. No lectin activity was 
detected for the recombinant full-size hSP–D and hNCRD with a C-terminal His6 tag 
(data not shown), which suggests that the presence of the His6 tag sequence at the CRD 
domain interferes with saccharide binding. The C-terminal His6 tag variants were 
therefore omitted from further functional analysis (3.2.2). 
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 Bacterial agglutination assay 3.2.2
The ability of the secreted tagged and untagged full-size hSP–D, hNCRD and hNCRD–
DsRed fusion protein to induce bacterial aggregation was determined by measuring 
light transmission through an E. coli suspension (2.2.6.2).  This assay was carried out 
using 2 µg/ml of each partially-purified rhSP–D variant obtained by ManNAc 
chromatography (3.1.2.1) or IMAC (3.1.2.2). The aggregation of E. coli cells was 
assessed by measuring the increase in turbidity following the addition of each protein in 
presence of 4 mM calcium. The same concentration of purified rhSP–D from a murine 
myeloma cell line (R&D Systems) was used as a positive control, and 100 mM maltose 
(Sigma–Aldrich) was used as a negative control. To avoid non-specific agglutination, an 
additional negative control was included using DsRed transiently expressed in tobacco 
leaves. Finally a bacterial suspension without the target proteins was used as the blank 
reference. These cells were suspended in sodium carbonate buffer plus 4 mM calcium 
and the baseline OD600 was 0.2–0.25. Figure 3.10 shows the results of the agglutination 
assays.  
 
    
Figure 3. 10: Time course of E. coli agglutination induced by rhSP–D variants 
(A) Secreted untagged full-size hSP–D produced by transient expression. (B) Secreted untagged full-size 
hSP–D produced in transgenic tobacco plants. (C) Secreted hNCRD–DsRed fusion protein produced by 
A B 
C 
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transient expression. The bacterial agglutination assay (2.2.6.2) was conducted at room temperature on 
flat-bottomed polystyrene microtiter plates in a total volume of 100 μl per well. All the experiments were 
carried out in the presence of 4 mM calcium. Turbidity (OD600) was monitored at 5-min intervals for 60 
min in a spectrophotometer. Gray line: E. coli suspension + 2 µg/ml purified rhSP–D from a murine 
myeloma cell line in PBS (positive control), Green line: E. coli suspension + 2 µg/ml partially-purified 
(A) untagged full-size hSP–D produced by transient expression, (B) untagged full-size hSP–D produced 
in transgenic tobacco plants, or (C) hNCRD–DsRed fusion protein, in TBS, Black line: E. coli suspension 
(blank control), Orange line: E. coli suspension + 2 µg/ml partially-purified (A) untagged full-size hSP–D 
produced by transient expression, (B) untagged full-size hSP–D produced in transgenic tobacco plants, or 
(C) hNCRD–DsRed fusion protein, in TBS plus 100 mM of maltose (negative control), Red line: E. coli 
suspension + DsRed (negative control). The mean values of six parallel measurements are shown and 
error bars represent standard deviations. 
 
As shown in Figure 3. 10A and B, an increase of turbidity due to bacterial agglutination 
was observed after the addition of 2 µg/ml purified untagged full-size hSP–D produced 
by transient expression (2.2.3.2) and in transgenic plants (2.2.3.4). Aggregation was 
calcium dependent and inhibited in the presence of 100 mM of maltose as reported 
(Kuan et al. 1992). Similar results were observed using 2 µg/ml purified hNCRD–
DsRed fusion protein (Figure 3.10C).  
Although previous studies have shown that trimeric NCRD can bind and agglutinate 
microbes in the same manner as the full–size protein (Clark et al. 2003; Strong et al. 
2002; Strong et al. 2003) the trimeric hNCRD produced in plants (with and without the 
N-terminal His6 tag) was unable to agglutinate bacteria (data not shown), suggesting 
that incorrect folding may prevent interactions between the CRDs and bacterial LPS. 
The same phenomenon probably explains why the full-size hSP–D with an N-terminal 
His6 tag lacks agglutination activity. These results confirmed that only the untagged 
full-size hSP–D and the hNCRD–DsRed fusion protein were functional in vitro. 
However, the absorbance levels achieved by the plant-derived rhSP–D variants were 
about half those achieved by the positive control, which may indicate that the plant-
derived proteins have lower states of oligomerization compared to the multivalent 
binding properties of the recombinant hSP–D purified from the murine myeloma cell 
line. 
 Thermal stability assay 3.2.3
Finally, the storage stability of the functional untagged full-size hSP–D and hNCRD–
DsReD fusion protein were tested in a thermal stability assay over two months, 
followed by ELISA (2.2.4.5), competitive ELISA (2.2.6.1) and bacterial agglutination 
assays (2.2.6.2) to monitor for degradation and loss of activity. Both the untagged full-
size hSP–D and the hNCRD–DsRed fusion protein produced by transient expression 
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were completely degraded after two months at all the temperatures tested and could not 
be detected by immunoblot, whereas the partially-purified untagged full-size hSP–D 
produced in transgenic tobacco plants was still detectable after two months (Table 3.4 
and Figure 3.11). 
 
Table 3.4: Amount of partially-purified untagged full-size hSP–D and hNCRD–DsRed fusion 
protein remaining after two months in storage 
The concentration was determined by ELISA (2.2.4.5) using 2 µg/ml purified fractions stored at 4°C, –
20°C and –80°C. SP–D was captured using a F(ab')2 rabbit anti-human SP–D antibody and detected using 
a biotin-labeled monoclonal mouse anti–human SP–D antibody, with purified rhSP–D from a murine 
myeloma cell line (R&D Systems) used as a positive control. Full-size hSP–DT: partially-purified 
untagged full-size hSP–D produced by transient expression in tobacco, Full–size hSP–DS: partially-
purified untagged full-size hSP–D produced in transgenic tobacco plants. Fusion proteinT: partially-
purified hNCRD–DsRed fusion protein produced by transient expression in tobacco. RT: room 
temperature. 
Amount (mg/l) 
 Full–size hSP–DT Fusion proteinT Full–size hSP–DS  
Starting point       RT: 30      RT:   5      RT:   567 
     4°C:   1     4°C:   2     4°C:   154 
Two months storage –20°C:   4 –20°C:   2 –20°C:   107 
 –80°C:   3 –80°C:   3 –80°C:   150 
  
 
 
 
 
                                         
 
Figure 3. 11: Immunoblot of partially-purified untagged full-size hSP–D and hNCRD–DsRed fusion 
protein after two months im storage 
Each lane was loaded with ~1 µg of purified untagged full-size hSP–D or hNCRD–DsRed fusion protein 
and the separated proteins were immunoblotted (2.2.4.4) and detected using a mouse monoclonal anti-
human SP–D primary antibody, a polyclonal rabbit anti-mouse Ig–AP secondary antibody conjugate and 
NBT/BCIP substrate.Development time: 1–10 min. Full-size hSP–DT: partially-purified untagged full-
size hSP–D produced by transient expression in tobacco, Full–size hSP–DS: partially-purified untagged 
full-size hSP–D produced in transgenic tobacco plants. Fusion proteinT: partially-purified hNCRD–
DsRed fusion protein produced by transient expression in tobacco. Starting point: purified fractions of 
untagged full-size hSP–D and fusion protein analyzed at RT at the beginning of the thermal stability 
assay. (1) partially-purified untagged full-size hSP–D produced by transient expression in tobacco, (2) 
partially-purified untagged full-size hSP–D produced in transgenic tobacco plants, (3) partially-purified 
hNCRD–DsRed fusion protein produced by transient expression in tobacco, M: pre-stained protein 1-kb 
marker (Fermentas), (+) positive control: recombinant hSP–D from a murine myeloma cell line (~5 μg, 
R&D Systems), (–) negative control: DsRed purified from tobacco plants after transient expression. 
Numbers on the post-storage gels refer to storage temperatures. 
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Based on these results, the untagged full-size hSP–D and the hNCRD–DsRed fusion 
protein produced by transient expression were not stable enough at any temperature to 
allow further functionality tests (Table 3.4). In contrast, although the amount of 
untagged full-size hSP–D produced in transgenic tobacco plants also declined after two 
months in storage, there was enough left to carry out functional assays (Table 3.4). This 
rhSP–D form performed well in the competitive ELISA (Table 3.5) achieving the same 
order of binding preference as the fresh protein (Table 3.3). However, this protein was 
not able to agglutinate bacteria after two months in storage (Figure 3.12). The OD600 of 
E. coli suspensions in the presence of plant-derived full-size untagged hSP–D (green 
line) was lower than the maltose competitor (orange line), confirming that agglutination 
was inhibited. Interestingly, the line corresponding to the partially-purified protein in 
the presence of the maltose inhibitor showed a slight increase in turbidity compared to 
the blank control (OD600 = 0.2–0.25) (Figure 3.12). This may have been caused by 
partial precipitation due to the TBS and CaCl2 remaining after dialysis. In conclusion, 
the thermal stability assay demonstrated that the untagged full-size hSP–D and the 
hNCRD–DsRed fusion protein behaved differently in terms of stability but neither 
remained stable for 2 months at 4°C, –20°C or even –80°C. Table 3.5 shows the results 
of the competitive ELISA after 2 months in storage at different temperatures, using 
partially-purified untagged full-size hSP–D produced in transgenic tobacco plants. 
Figure 3.12 shows the bacterial agglutination assay after 2 months in storage at 4°C, 
using partially-purified untagged full-size hSP–D from transgenic tobacco plants and 
identical behavior was observed at the other temperatures. 
Table 3.5: Competitive ELISA of untagged full-size hSP–D
s
 after two months in storage.  
The IC50 values were determined using 2 µg/ml of purified fractions stored at 4°C, –20°C and –80°C. 
Three independent assays were carried out using 0–500 mM of the competing saccharides in presence of 
5 mM calcium chloride. SP–D was detected using a mouse monoclonal anti-human SP–D primary 
antibody, a polyclonal rabbit anti-mouse Ig–AP secondary antibody conjugate and NBT/BCIP substrate. 
RT: room temperature. ManNAc: N-acetylmannosamine. 
 
Saccharides (IC50 mM) 
 ManNAc Maltose Glucose Galactose 
Starting point (RT) 3 3 7 34 
     4°C 2 3 5 10 
– 20°C 2 4 5 12 
– 80°C 2 3 5 10 
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Figure 3. 12: Time course of E. coli agglutination by untagged full-size hSP–DS after two months in 
storage at 4°C 
Bacterial agglutination (2.2.6.2) was carried out at room temperature in flat-bottomed polystyrene 
microtiter plates in total volume of 100 μl per well using purified untagged full-size hSP–D produced in 
transgenic tobacco plants. All experiments were carried out in presence of 4 mM calcium. The turbidity 
was monitored at 600 nm in 5-min intervals for 60 min in a spectrophotometer. Gray line: E. coli 
suspension + 2 µg/ml purified rhSP–D from a murine myeloma cell line in PBS (positive control), Green 
line: E. coli suspension + 2 µg/ml partially-purified untagged full-size hSP–D produced in transgenic 
tobacco plants in TBS, Black line: E. coli suspension (blank control), Orange line: E. coli suspension + 2 
µg/ml partially-purified untagged full-size hSP–D produced in transgenic tobacco plants in TBS plus 100 
mM of maltose (negative control), Red line: E. coli suspension + DsRed (negative control). The mean 
values of four parallel measurements are shown and error bars represent standard deviations. 
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 Discussion 4
This PhD project had two major aims: the establishment of a plant-based expression 
platform for high-level rhSP–D production (3.1) and the characterization of rhSP–D 
variants for C-type lectin activity (3.2). 
In the first part, expression constructs with a signal peptide for secretion to the apoplast 
were found to be suitable for the production of diverse rhSP–D variants (full-size hSP–
D, hNCRD and a hNCRD–DsRed fusion protein in tobacco) (3.1.1.2). Furthermore, 
purification conditions were established for secreted rhSP–D variants with and without 
a His6 tag (3.1.2). Untagged full-size hSP–D gave the highest yields by transient 
expression, followed by the full-size hSP–D with an N-terminal His6 tag and the 
untagged hNCRD. The secreted rhSP–D variants lacking a His6 tag were functional 
lectins, i.e. they bound to N-acetylmannosamine during ManNAc purification (3.1.2.1). 
Secreted rhSP–D variants with N-terminal or C-terminal His6 tags were also purified by 
IMAC (3.1.2.2). However, both procedures were only capable of partial purification. 
The recovery of the proteins was generally poor (9.7–14% for the untagged rhSP–D 
variants and 0.7–13% for the tagged variants). Nevertheless, immunoblot analysis 
confirmed the expected sizes of trimeric full-size hSP–D (~170 kDa), trimeric hNCRD 
(~15–16 kDa) and the hNCRD–DsRed fusion protein (~168 kDa). 
In the second part, the secreted rhSP–D variants were tested for C-type lectin activity 
based on their saccharide affinity binding (3.2.1) and ability to induce bacterial 
agglutination (3.2.2). The untagged and N-terminal His6-tagged rhSP–D variants 
showed high-affinity binding to N-acetylmannosamine and maltose and low affinity for 
galactose (3.2.1). Only the untagged full-size hSP–D and the hNCRD–DsRed fusion 
protein were able to agglutinate E. coli (3.2.2). A thermal stability assay indicated that 
all the recombinant proteins were unstable during two months of storage (3.2.3). 
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4.1 Expression of rhSP–D in tobacco leaves 
 
The first challenge when establishing a tobacco-based production platform was to find 
the subcellular location most suitable for full-size hSP–D, hNCRD and the hNCRD–
DsRed fusion protein. Subcellular targeting is one of the most important factors 
affecting the yields of recombinant proteins because the cell compartment influences 
folding, assembly and post-translation modification, all of which contribute the protein 
stability and yield (Twyman et al. 2003). In its natural environment, hSP–D is secreted 
into the alveolar space, and therefore requires an N-terminal signal peptide that allows 
movement through the secretory pathway (Kishore et al. 2006). This is where folding 
and post-translational modifications occur, including to formation of disulfide bonds 
and glycans (Leth–Larsen et al. 1999; Vuk–Pavlovic et al. 2001). Several plant-derived 
recombinant human antibodies that usually pass through the endomembrane system 
have been targeting to the apoplast and accumulated to high levels suggesting this 
principle may also be suitable for rhSP–D (Twyman et al. 2003). Considering the 
complexity of hSP–D maturation, the yields, stability and biological activity of the 
rhSP–D variants were evaluated following expression in tobacco leaves and secretion to 
the apoplast.   
Some proteins accumulate to higher levels in the cytosol than the apoplast (Twyman 
2004). The cytosol lacks the machinery to produce certain post-translational 
modifications, including glycans, but the neck and CRD domains of hSP–D are not 
glycosylated and do not require any other post-translational modifications, but 
nevertheless maintain the biological activity of the protein (Strong et al. 2003). 
Mutation of the N-glycan acceptor site in the collagen region of rat SP–D has also 
shown that it is unnecessary for secretion, dodecamer formation or interaction with 
microorganisms (Crouch et al. 2000). In addition N-terminal disulfide bridges are 
important for higher-order multimer formation, but are not essential for many of the 
biological activities of trimeric hSP–D (Clark and Reid 2002; Knudsen et al. 2007; 
Zhang et al. 2002). Because post-translational modifications are not required for hSP–D 
activity, the cytosol was also tested for the production of the rhSP–D variants.  
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 Expression of untagged and His6-tagged full-size hSP–D and hNCRD 4.1.1
As described earlier (3.1.1.1, 3.1.1.2) only the apoplast-targeted rhSP–D variants 
accumulated to high levels in tobacco leaves after transient expression. ELISA analysis 
confirmed yields of 30–180 mg/kg FLW for the apoplast variants whereas the cytosolic 
versions could not be detected (3.1.1.2, Figure 3.3A and B). This may reflect the 
negative redox potential in the cytosol, incorrect protein folding and/or the ubiquitin–
proteasome pathway that may degrade the proteins completely (Anelli and Sitia 2008). 
Immunoblot analysis of plant crude extracts under non-reducing conditions showed that 
the rhSP–D variants accumulated in the apoplast. His6-tagged and untagged full-size 
hSP–D displayed bands with molecular weights of ~37–40 kDa, ~80 kDa and ~170 kDa 
corresponding to the monomer, dimer and trimer of full–size hSP–D (Sorensen et al. 
2009; Oberley et al. 2004) (3.1.1.2, Figure 3.3C). SP–D trimers typically migrate at a 
higher apparent molecular weight (130–200 kDa) due to disulfide bonds crosslinking 
the collagenous domains (Oberley et al. 2004). Higher multimers of full-size hSP–D 
(520 kDa) were not well-defined because the limit of the separation ranges in SDS-
PAGE.  
Corresponding immunoblots for the His6-tagged and untagged hNCRD revealed the 
characteristic non-collagenous fragment of ~15–18 kDa corresponding to the trimeric 
neck and CRD domains (3.1.1.2, Figure 3.3D) as previously reported in E. coli (Madan 
et al. 2001; Crouch et al. 2005). Diffuse bands of ~35 and ~80 kDa were also detected, 
apparently related to the formation of aberrant disulfide bonds between the CRDs 
(Crouch et al. 2005; 1996; Madan et al. 2001). 
The discrepancy between the high accumulation levels of the secreted rhSP–D variants 
(3.1.1.2, Figure 3.3A) and the low band intensity observed in the immunoblots (3.1.1.2, 
Figure 3.3C and D) could indicate that the protein concentration is overestimated by 
ELISA due to plant-derived contaminations that interfere with the assay. This 
hypothesis was confirmed in further experiments using purified untagged full-size hSP–
D from transgenic tobacco plants (4.3.1). 
 Expression of the hNCRD–DsRed fusion protein 4.1.2
The hNCRD–DsRed fusion protein was produced by transient expression in tobacco 
leaves (3.1.1.2). DsRed is often used in biotechnology and cell biology to label or track 
fusion proteins. However, DsRed is an obligate tetramer in vitro and in vivo and 
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therefore often causes the artificial oligomerization of recombinant fusion proteins 
(Campbell et al. 2002). DsRed was used in these experiments to increase the 
oligomerization state of the hNCRD deliberately thus promoting its activity. 
Immunoblot analysis showed an upper band of ~170 kDa (3.1.1.2, Figure 3.3E) in 
contrast to the trimeric hNCRD of ~16 kDa. The monomeric form of DsRed has a 
molecular weight of ~26 kDa, and has the ability to form complex proteins of at least 
four oligomerization states. Taking into account that trimeric NCRD have similar 
molecular weight under reducing and non-reducing conditions (Madan et al. 2001, 
Crouch et al. 2005), the band detected in this experiment could correspond to a ~168 
kDa protein reflecting the self-assembly of the DsRed monomer, i.e. 4x (26 + 16 kDa) 
(Baird et al. 2000).  The fuzzy band of ~40 kDa may represent the monomeric hNCRD–
DsRed fusion protein of ~42 kDa and the ~15 kDa band could be associated with a 
degradation product generated by endogenous proteases in the apoplast. 
4.2 Stable transformation of tobacco plants 
 
The apoplast was confirmed as a suitable compartment rhSP–D accumulation in the 
transient expression experiments, so transgenic tobacco plants were generated using the 
constructs that achieved the highest yields of each recombinant protein. In T1, the 
maximum yields were up to 60 mg/kg FLW for the full-size hSP–D with N-terminal 
His6 tag and 40 mg/kg FLW for the untagged hNCRD. In the T2 generation, these 
increased to 80 and 60 mg/kg FLW, respectively, suggesting that the yields may depend 
in part on the transgene copy number and/or zygosity.  
The yields of the untagged full-size hSP–D (50 mg/kg FLW) and hNCRD with an 
N-terminal His6 tag (30 mg/kg FLW) tended to remain constant between the T1 and T2 
generations but the yield of the untagged full-size hSP–D increased sixfold between the 
T2 and T3 generations to ~200–300 mg/kg FLW. However, this was also likely to 
reflect the overestimation of protein concentration in the ELISA due to plant-derived 
contaminants interfering with the assay as discussed later (4.3.1).  
The yields of untagged and N-terminal His6-tagged full-size hSP–D in the T2 generation 
of transgenic tobacco plants were 10–16 times higher than the maximum yields 
achieved in mammalian cell lines, which are typically in the range of 1–5 mg/l using 
HEK293 (Van Eijk et al. 2011). In case of untagged hNCRD, the yield in the T2 
generation was ~1.5 times higher than the maximum yield of NCRD in E. coli, which is 
40 mg/l (Crouch et al. 2006).  
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The ability of transgenic tobacco plants to produce SP–D variants at higher yields than 
both mammalian cells and E. coli suggests that plants are promising candidates for the 
production of diverse forms of rhSP–D. However, it is also necessary to consider 
downstream processing (4.3). Table 4.1 compares the maximum yields of rhSP–D 
achieved in plants, mammalian cells and microbial platforms. 
  
Table 4. 1: Comparison of maximum rhSP–D yields achieved in heterologous expression systems 
Expression platform Yields  References 
 Full-size hSP–D  
Tobacco 80 mg/kg 
(*)
  
HEK293  5 mg/l Van Eijk et al. (2011) 
CHO–K1 2 mg/l Chiba et al. (2002) 
 NCRD  
Tobacco 60 mg/kg  
(**)
  
E. coli 40 mg/l Crouch et al. (2006) 
P. pastoris 7 mg/l Hakkason et al. (1999) 
(*)
 Full-size hSP–D with N-terminal His6 tag  
(**) 
Untagged hNCRD 
 
 
4.3 Purification of rhSP–D variants from tobacco leaves  
 
Downstream processing is the major bottleneck in pharmaceutical production processes 
and can account for up to 80% of the total cost of production for a therapeutic protein 
(D‟Souza et al. 2013, Raven et al. 2015; Platis and Labrou 2008). The goal of 
downstream processing is to recover the highest amount of pure target protein with the 
smallest number of steps and at lowest cost (Chen et al. 2008). In this context, the 
purification of hSP–D, hNCRD and the hNCRD–DsRed was addressed.  
 Purification of the untagged full-size hSP–D and hNCRD by ManNAc 4.3.1
chromatography 
 
Human SP–D is usually purified from bronchoalveolar lavage or amniotic fluid by 
carbohydrate-affinity chromatography using its lectin activity to bind carbohydrates 
present on the resin (Sorensen et al. 2009). ManNAc chromatography using 
N-acetylmannosamine was therefore tested for the purification of the recombinant 
proteins (3.1.2.1, Figure 3.3A). This method is reported to improve the recovery of 
purified hSP–D compared to maltose-affinity purification, i.e. >90% compared to ~60% 
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with most of the protein lost during the washing steps (Sorensen et al. 2009; Strong et 
al. 1998). The best flow rate for the purification of plant-derived rhSP–D variants was 
determined by performing ManNAc chromatography on an ÄktaExplorer 10 system at 
flow rates from 30 to 300 cm/h. This revealed that higher flow rates reduced recovery 
because the efficiency of binding was reduced (3.1.2.1, Figure 3.4). The slowest flow 
rate tested (30 cm/h) was better for rhSP–D isolation. Sorensen et al. (2009) found that 
a slow flow rate of 1 ml/min was optimal for the isolation of hSP–D from amniotic 
fluid. Crouch et al. (2005) used a flow rate of 0.5 ml/min to purify an hNCRD from 
E.coli inclusion bodies. These experiments demonstrated the importance of slow flow 
rates during the ManNAc chromatography to increase the opportunity for binding 
between SP–D and N-acetylmannosamine.  
Slower flow rates also increase the risk of contaminants in the plant extracts, such as 
phenolics and alkaloids, fouling the resin.  Therefore, the ÄktaExplorer 10 system was 
replaced with a bench-scale gravity-flow column. As described above (3.1.2.1), 
ManNAc affinity chromatography was then used to recover untagged full-size hSP–D 
and hNCRD. The bound proteins were eluted by replacing Ca
2+
 with Mn
2+
 in the elution 
buffer (Sorensen et al. 2009). This approach can recover up to 90% of the trimeric form 
of hSP–D from amniotic fluid, but only ~9.7% of the trimeric full-size hSP–D and 
~14% of the hNCRD were recovered from plant extracts. The elution fractions 
contained ~24 mg/l of the untagged full-size hSP–D and ~34 mg/l of the untagged 
hNCRD. The recombinant proteins were lost in the flow through (~15 mg/l) and 
washing steps (~9 mg/l) as shown by Coomassie staining (3.1.2.1, Figure 3.5A and C). 
However, a significant proportion of these proteins probably remained bound to the 
resin, explaining the low protein concentration in the elution fractions. In addition, the 
presence of phenolics and alkaloids probably caused resin fouling, making the 
purification of target proteins even more difficult (Bai and Glatz 2003; Menkhaus et al. 
2004; Valdes et al. 2003). These results showed that ManNAc chromatography can only 
achieve the partial purification of SP–D variants produced in plants. 
Immunoblot analysis under non-reducing conditions revealed the trimeric hNCRD 
(3.1.2.1, Figure 3.4D) with an apparent molecular weight of ~15–16 kDa, which is 
similar to the size reported when the same protein was expressed in E. coli (Madan et al. 
2001; Crouch et al. 2005). The untagged full-size hSP–D (3.1.2.1, Figure 3.5B) 
produced a band with a molecular weight of ~170 kDa corresponding to the full-size 
hSP–D trimer under non-reducing conditions (Sorensen et al. 2009; Oberley et al. 2004; 
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Leth–Larsen et al. 1999). However, the band representing the monomer (~35 kDa) was 
smaller than the 40-kDa monomer band reported by Sorensen et al. (2009) and Leth–
larsen et al. (1999). This difference of 2–5 kDa may indicate the partial degradation of 
the protein by endogenous proteases present in the apoplast of tobacco leaves during the 
preparation of the sample for ManNAc purification. Recombinant protein degradation 
has been reported in tobacco and other plant species (Ma et al. 1994; Sharp and Doran 
2001; Villani et al. 2009; Schiermeyer et al. 2009). Furthermore, immunoblot analysis 
of untagged full-size hSP–D (3.1.2.1, Figure 3.4B) also showed an extra band of ~46 
kDa, which may correspond to an atypical glycosylated monomeric version generated 
by plant-specific glycosylation. A similar 46-kDa glycan variant was reported by Leth–
Larsen (2005), whereas Mason et al. (1998) detected a 50-kDa variant generated by 
post-translation modification in the bronchoalveolar lavage fluid.  
Although protein synthesis is conserved between plants and mammals, some differences 
in glycosylation are exclusive to plants. Plant-derived recombinant human proteins 
usually contain the carbohydrate groups β(1,2)xylose and α(1,3)fucose which are not 
present in animals, and lack terminal galactose and sialic acid residues that are usually 
found in the human glycoproteins (Twyman et al. 2003). These minor differences in 
post-translational modification can induce immune responses when plant-derived 
recombinant proteins are administered to some mammals, although such effects have 
not been demonstrated in humans (Chargelegue et al. 2000). Nevertheless, one strategy 
to avoid plant-specific glycosylation is to retrieve hSP–D from the Golgi apparatus and 
return it to the endoplasmic reticulum (ER), which can be achieved by adding a 
C-terminal ER retention signal (SEKDEL) to the target protein (Fischer et al. 1999). 
Recombinant proteins can accumulate in the ER to higher levels than those expressed in 
the apoplast or cytosol (Fischer et al. 2003). However, ER retention was not considered 
in this study because the addition of a SEKDEL peptide to the C-terminus of full-size 
hSP–D could interfere with the CRD, which is precisely the outcome when we tested 
variants with the His6 tag placed at the C-terminus (4.4.1).  
Although the untagged full-size hSP–D and hNCRD could be detected by immunoblot, 
they could not be detected by Coomassie staining so it was difficult to estimate their 
purity. To determine whether this issue was caused by inaccurate ELISA quantitation or 
the sensitivity of Coomassie staining, ManNAc chromatography was used to purify 
untagged full-size hSP–D from T3 transgenic plants, which achieved apparent sixfold 
higher yields and the T2 and T1 generations (3.1.1.3). The concentration of untagged 
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full-size hSP–D in the elution fraction was ~500 mg/l as determined by ELISA, but 
once again no bands were detected by Coomassie staining (data not shown). This 
discrepancy between the high concentration determined by ELISA and the absence of 
stained bands following SDS–PAGE suggested that the purified protein concentration 
was overestimated by ELISA (perhaps due to the presence of contaminants in the plant 
extract that interfered with the assay). Alternatively, the Coomassie stain might be 
unsuitable for the detection of rhSP–D because it is known to bind inefficiently to 
glycoproteins. 
The ELISA was carried out according to Sorensen et al. (2009), who captured SP–D 
using a polyclonal antibody followed by detection with a monoclonal antibody 
recognizing the neck and CRD domains. SP–D quantification is challenging and there 
are many conflicting reports regarding its concentration in bronchoalveolar lavage or 
amniotic fluid (Hull et al. 1997; Phelps et al. 1991; Limper et al. 1994) reflecting the 
variable dilution factors caused by the lung washing procedure (Holmskov 2000). One 
option to increase the accuracy of quantitation is to improve the purity of plant-derived 
rhSP–D and measure the exact concentration by amino acid analysis. 
The low sensitivity of Coomassie staining was addressed by repeating the SDS–PAGE 
experiments but using the more sensitive silver staining procedure, which can detect 
proteins in the low nanogram range. The silver ions in the stain bind to specific 
functional groups in hSP–D, such as the terminal carboxylic acid in the CRD, sulfhydryl 
groups at the N-terminus and lysine residues in the collagenous domain (Life 
technologies 2014). Silver staining revealed a ~15–16 kDa band (3.1.2.3 Figure 3.8A 
and B). The intensity of the plant-derived untagged full-size hSP–D was weaker than 
the positive control from a murine myeloma cell line (3.1.2.3 Figure 3.5) and the 
recurrence of this phenomenon supports the conclusion that the protein concentration 
determined by ELISA is overestimated. The band was similar in size the characteristic 
trimeric hNCRD produced in bacteria (Madan et al. 2001; Crouch et al. 2005) 
suggesting that endogenous proteases in the apoplast may degrade the untagged full-size 
hSP–D. Cooley et al. (2008) reported the C-terminal cleavage of SP–D by an active 
neutrophil serine protease in children with cystic fibrosis. Serine proteases have been 
identified in tobacco BY-2 suspension cells (Navarre et al. 2012), and in the roots 
(Komarnytsky et al. 2006) and leaves (Rivard et al. 2006) of whole plants, with high 
activity in the acidic pH of the apoplast. Bratcher et al. (2012) described the proteolytic 
degradation of the collagenous region of SP–D by metalloproteases, and these have also 
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been detected in tobacco leaves (Kang et al. 2010), which would explain how the 
collagen domain of full-size hSP–D can be cleaved without affecting the trimerization 
properties of the neck domain. Apoplast serine proteases and metalloproteases may 
therefore remove the N-terminal and collagen regions of untagged full-size hSP–D 
produced in tobacco, explaining the detection of a ~15–16 kDa non-collagenous 
fragment. 
 Purification of the His6-tagged full-size hSP–D, hNCRD and hNCRD–4.3.2
DsRed fusion protein by IMAC 
 
Conventional hSP–D purification involves the use of carbohydrate-based affinity 
chromatography (Strong et al. 1998; Sorensen et al. 2009; Dodagatta et al. 2014). 
However, the protein can be difficult to elute if it binds strongly to the resin, which 
leads to low recovery rates and increases the cost of purification. IMAC was therefore 
used as an alternative approach to purify SP–D variants carrying a His6 tag (3.1.2.2). 
IMAC is a versatile method that rapidly purifies tagged proteins, achieving up to 100-
fold enrichment in a single purification step with up to 95% purity (Sureshkumar and 
Priya 2012). Previous studies have shown that IMAC can be used to purify trimeric 
NCRD from E. coli or CHO–K1 cells (Matalon et al. 2009; Crouch et al. 2005).  
Following purification by IMAC, non-reducing SDS-PAGE and immunoblotting 
revealed a monomer band of ~37 kDa, similar to the 40-kDa monomer band detected by 
Sorensen et al. (2009) and Leth–Larsen et al. (2005). The difference of 3 kDa may 
indicate partial degradation of the product by endogenous plant proteases. The trimeric 
form was represented by a band of ~170 kDa (3.1.1.2, Figure 3.6A and B) similar to 
earlier reports (Sorensen et al. 2009; Oberley et al. 2004; Leth–larsen et al. 2005). The 
trimeric His6-tagged hNCRD form appeared as a band with an apparent molecular 
weight of ~15–16 kDa, also similar to earlier reports (Madan et al. 2001; Crouch et al. 
2005) (3.1.2.2, Figure 3.6C and D). For each of the His6-tagged rhSP–D variants, a 
strong background signal was detected in the flow-through and wash fractions after 
staining the gel with Coomassie. The proteins appear to bind so strongly to the Ni
2+
 
resin that even 500 mM imidazole was unable to promote further elution, suggesting 
that IMAC achieves only partial purification of SP–D variants produced in plants. The 
recovery rates were therefore low, i.e. ~0.8% for the His6-tagged full-size hSP–D and 
~11% for the His6-tagged hNCRD. The resulting concentrations in the elution fraction 
were ~16 mg/l for the full-size variant with an N-terminal tag, ~2 mg/l for the full-size 
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hSP–D variant with a C-terminal tag, ~27 mg/l for hNCRD with an N-terminal tag and 
~10 mg/l for hNCRD with a C-terminal tag (3.1.2.2, Table 3.2). 
The presence of DsRed in the fusion protein resulted in higher recovery values using 
NTA–agarose coupled to Cu2+ (3.1.2.2, Figure 3.7). This confirms the ability of DsRed 
to bind selectively to copper ions during copper–based affinity chromatography (Rahimi 
et al. 2007).  
These data suggest that contaminants in the plant extract and the strong binding of  
rhSP–D variants to the chromatography matrix (4.3.1 and 4.3.2) are significant 
bottlenecks that make the production of rhSP–D in plants more expensive than  
mammalian and microbial platforms. Similar bottlenecks have been observed for the 
purification of other proteins from the same family of lectins in plants, and diverse 
chromatography steps have been tested, e.g. affinity chromatography, ion-exchange 
chromatography, hydrophobic interaction chromatography, and gel filtration (Pohleven 
et al. 2012). The low purity and recovery values suggest that large-scale production will 
not be economical (Nascimiento et al. 2012; Alves et al. 2000). Affinity 
chromatography can be inhibited by the pigments, oils and other metabolites present in 
plants that affect the function of the resin (Nascimiento et al. 2012; de Santana et al. 
2008). Non-chromatographic separation methods have therefore been developed for the 
purification of plant lectins, e.g. membrane technology, magnetic separation, affinity 
precipitation, and aqueous two-phase extraction (Nascimiento et al. 2012; Rosa et al. 
2007). These methods could also be used as alternatives to improve the purification of 
the rhSP–D from tobacco leaves. 
 
4.4 Characterization of rhSP–D variants for C–type lectin activity 
 
Human SP–D plays multiple roles in the innate immune system and acts as a pattern 
recognition molecule to bind a variety of ligands present on the surface of microbes and 
dying cells, including bacterial LPS, fungal mannan, viral surface proteins and 
mycoplasma in lipids (Vasta 2008). These associations include interactions with the 
host cells that promote microbial aggregation, cellular uptake and microbial inhibition, 
and also modulate cytokine production by phagocytes in response to inflammation, 
apoptotic activity and acquired immunity (Crouch et al. 2006). In the present study, the 
functionality of three rhSP–D variants (full-size hSP–D, hNCRD and a hNCRD–DsRed 
fusion protein) was evaluated in terms of their C-type lectin activity mediated the CRD 
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in the presence of calcium, i.e. their ability to bind different saccharides and to 
agglutinate bacteria.  
The IC50 values determined by competitive ELISAs showed that all three plant-derived 
rhSP–D variants have the same saccharide affinity as native hSP–D derived from 
bronchoalveolar lavage or amniotic fluid. However, only the untagged full-size hSP–D 
and the fusion protein were able to bind and agglutinate E. coli.  
 Plant-derived rhSP–D variants have the same saccharide binding affinity 4.4.1
as native hSP–D 
 
The saccharide preferences of rhSP–D variants were determined by competitive ELISA 
using mannan from Saccharomyces cerevisiae (3.2.1) as previously reported (Sorensen 
et al. 2005; Crouch et al. 2005). Untagged full-size hSP–D produced by transient 
expression showed the same saccharide preferences as native hSP–D, with a strong 
preference for N-acetylmanosamine followed by maltose > glucose > galactose (3.2.1, 
Table 3.3 ). N-acetylmanosamine was the most potent competitor, consistent with early 
studies using native hSP–D derived from amniotic fluid (Sorensen et al. 2009). Maltose 
was a close second preference for untagged full-size hSP–D, also as previously reported 
for porcine SP–D (Sorensen et al. 2009) and rat SP–D (Persson et al. 1989).  Full-size 
hSP–D with an N-terminal His6 tag showed the same preferences (3.2.1, Table 3.3). 
The least preferred saccharide was galactose, which was approximately 20 times less 
potent than N-acetylmannosamine in competition with mannan, as previously reported 
(Sorensen et al. 2005; Thormann et al. 2007; Crouch et al. 2005). These findings 
confirmed the presence of the mannose/C-type lectin motif in the CRD domain, which 
is responsible for the saccharide binding activity of SP–D (Crouch et al. 1998). 
Human NCRD also showed the same preferences as native hSP–D (Crouch et al. 2006; 
Crouch et al. 2005, Sorensen et al. 2005) but there were no significant differences in 
binding preference (3.2.1, Table 3.3). This may reflect the incorrect folding of the 
proteins, interfering with the CRD-carbohydrate interaction. 
The hNCRD–DsRed fusion protein displays the same saccharide preferences as the 
other forms of the protein (3.2.1) albeit with higher IC50 values of 8–46 mM. This may 
reflect the presence of several CRDs in the tetrameric protein resulting from the 
assembly of DsRed (Baird et al. 2000). The hypothetical tetrameric fusion protein may 
bind with higher affinity to bacterial mannan due to the presence of multiple CRDs, 
such that only high concentrations of the saccharide competitors can achieve disruption. 
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In addition, previous studies have demonstrated that the capacity for bridging 
interactions between hSP–D and ligands depends on an appropriate oligomerization of 
trimeric subunits. Human SP–D multimers have a higher binding affinity to a variety of 
ligands and are considerably more potent than trimeric hSP–D (Crouch et al. 1998). A 
schematic representation of the tetrameric hNCRD–DsRed fusion protein is shown in 
Figure 4.1. Full-size hSP–D and hNCRD with a C-terminal His6 tag failed to bind to 
mannan-coated plates, indicating that the C-terminal tag interfered with the C-type 
lectin activity.             
                 
 
 
 
Figure 4.1: Schematic representation of the tetrameric hNCRD–DsRed fusion protein 
The fusion protein starts as a monomeric polypeptide but the self-assembly of DsRed generates a 
tetrameric fusion protein. The final anticipated molecular weight is ~168 kDa. CRD: carbohydrate 
recognition domain, ND: neck domain 
 Untagged full-size hSP–D and the fusion protein agglutinate E. coli 4.4.2
SP–D plays a central role in the protection of the lungs against respiratory infections by 
binding to glycoconjugates on the surface of viruses, bacteria, yeast, and fungi (Crouch 
2000; Lawson and Reid 2000; Crouch and Wright 2001). These interactions involve the 
lectin-dependent mechanisms promotion of internalization and microbial killing (Ofek 
et al. 2000) as well as microbial agglutination, a process that can stimulate phagocytosis 
by macrophages. SP–D agglutinates microbes effectively as a dodecamer with CRD 
domains oriented in multiple directions. The SP–D CRDs bind with high affinity to LPS  
on the surface of e.g. E. coli, Klebsiella pneumoniae and Pseudomonas aeruginosa 
(Kuan et al. 1992; Lim et al. 1994; Kishore et al. 1996) leading to agglutination. To 
determine whether plant-derived rhSP–D could function in a similar manner, its ability 
to promote bacterial agglutination was examined (3.2.2). 
CRD 
ND 
DsRed monomer 
Self–assembly of  
 DsRed monomers 
Monomeric 
hNCRD–DsRed fusion protein 
MW: ~42 kDa 
Tetrameric  
hNCRD–DsRed fusion protein 
MW: ~168 kDa 
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The partially-purified untagged full-size hSP–D was able to bind and agglutinate E. coli 
strain DH5α (Figure 3.10A, B) as previously reported (Kuan et al. 1992; Hartshorn et 
al. 2002). Similarly, the purified hNCRD–DsReD fusion protein produced by transient 
expression also achieved bacterial agglutination (Figure 3.10C). The increase in 
turbidity following the addition of rhSP–D was associated with the binding and 
agglutination of E. coli, which was calcium-dependent and inhibited by maltose.  
The bacterial agglutination activity of the partially-purified untagged full-size hSP–D 
from transgenic tobacco plants suggests that the hNCRD folds correctly and is 
functional (Figure 3.10B). This truncated fragment is produced when the N-terminal 
and collagenous domains are degraded by plant proteases (3.1.2.3, Figure 3.8). Previous 
studies have shown that trimeric NCRD is active in vitro and in vivo because it retains 
the biological activity of the full–size protein (Strong et al. 2003; Madan et al. 2001; 
Singh et al. 2003).   
The bacterial aggregation activity of the hNCRD–DsRed fusion protein supported the 
generation of a tetrameric protein (3.2.2, Figure 3.10C), which is necessary for high-
affinity binding and agglutination (Crouch et al. 2000). Although previous studies have 
shown that trimeric NCRD can bind and agglutinate microbes in the same way as the 
full-size protein (Clark et al. 2003; Strong et al. 2002; Strong et al. 2003), no 
agglutination was observed for any of the truncated hNCRD forms evaluated in this 
project, probably due to incorrect folding reflecing the formation of aberrant disulfide 
bonds in the CRDs, resulting the domain being oriented in a manner that prevents 
effective interactions with LPS. In the same way, full-size hSP–D with an N-terminal 
His6 tag may not fold properly, generating a non-functional trimeric protein also unable 
to achieve bacterial agglutination. 
The bacterial agglutination activity of the untagged full-size hSP–D and the hNCRD–
DsRed fusion protein was lower than the positive control from the murine myeloma cell 
line. Recombinant hSP–D from mammalian cells can form dodecamers or even higher 
multimerization states with strong bacterial agglutination effects. The lower 
agglutination effects observed for the plant-derived proteins may reflect the presence of 
contaminants from the plant extracts that interfere with agglutination. The absorbance 
values of the tetrameric hNCRD–DsRed fusion protein (0.30–0.35) were lower than the 
positive control value (0.45–0.48) suggesting that the murine protein may assemble into 
a highly-oligomerized structure such as an octadecamer (>512 kDa) increasing the 
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number of CRDs compared to tetrameric hNCRD–DsRed fusion protein produced in 
plants (Nadesalingam et al. 2003). 
 Long-term storage of untagged full-size hSP–D and the hNCRD–DsRed 4.4.3
fusion protein 
 
The development of stable pharmaceutical formulations containing recombinant 
proteins is one of the final critical steps in downstream processing. The integrity of the 
purified protein must therefore be maintained during storage and treatment. However, 
proteins are complex molecules which may assemble into oligomeric structures, so it 
can be difficult to identify conditions that maintain stability and efficacy (Chang and 
Hershenson 2002). In order to achieve this goal, it was necessary to determine the 
thermal stability of the functional untagged full-size hSP–D (produced by transient 
expression and in transgenic plants) and the fusion protein (produced by transient 
expression). Each protein was evaluated in terms of concentration and C-type lectin 
activity after two months in storage at different temperatures (4°C, –20°C and –80°C). 
In all cases, there was a significant loss of protein during storage (3.2.3, Table 3.4). 
Both the full-size hSP–D and the fusion protein produced by transient expression were 
completely undetectable after two months in storage at all three temperatures (3.2.3, 
Figure 3.11). This may reflect protein denaturation rather than degradation, i.e. the neck 
and CRD domains may no longer be recognized by the specific monoclonal anti-human 
SP–D antibody. The concentration of the untagged full-size hSP–D produced in 
transgenic tobacco plants also fell dramatically, but the remaining portion retained its 
saccharide binding activity and preferences after two months in storage (3.2.3, Figure 
3.11 and Table 3.5). The higher IC50 values detected at the starting point of the 
competitive ELISA assay for glucose and galactose demonstrated that rhSP–D binds 
selectively to N-acetylmannosamine and maltose. However, the IC50 values for 
galactose declined after two month in storage at different temperatures, suggesting the 
protein had denaturated thus affecting the specificity and selectivity of CRD–
carbohydrate recognition. Accordingly, the partially-purified untagged full-size hSP–D 
produced in transgenic tobacco plants lost all its bacterial agglutination activity after 
storage for two months at 4°C, –20°C or –80°C. The effect was inhibited by the 
presence of maltose, again suggesting protein denaturation had occured after two 
months in storage (3.2.3, Figure 3.12). 
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 Outlook 5
The work described in this thesis led to the establishment of a plant-based production 
platform for three rhSP–D variants (full-size hSP–D, hNCRD and an hNCRD–DsRed 
fusion protein) (3.1). The partial purification of the rhSP–D variants was achieved and 
preliminary functional analysis was completed (3.2).  
One bottleneck encountered was the determination of optimal conditions for purification 
by ManNAc chromatography and IMAC. The recombinant proteins bound strongly to 
each matrix, and binding was also affected by plant-derived contaminants, leading to 
low recovery. Alternative strategies may therefore be necessary to optimize the 
purification step. These strategies would first need to reduce protein degradation caused 
by the activity of proteases in the apoplast, which might be achieved by extracting the 
proteins at 4°C and including protease inhibitors in the extraction buffer (Schiermeyer 
et al. 2005; Komarnytsky et al. 2006; Rivard et al. 2005). Second, plant-derived 
impurities could be removed by fractional precipitation with ammonium sulphate before 
the extract is applied to the chromatography column (Nascimiento et al. 2012). Tobacco 
extracts also contains lectins (Delporte et al. 2013), which should be removed to avoid 
co-purification with SP–D during ManNAc chromatogrpahy. Sureshkumar and Priya 
(2012) reported the purification of a plant lectin by IMAC, which could be introduced 
as an initial purification step to reduce the concentration of plant lectins in the extract. 
Serial carbohydrate affinity chromatography with two or more carbohydrate adsorbents 
in sequential steps could also be used to remove lectins (Chen et al. 1999; Kato et al. 
2011). Third, although ManNAc and IMAC affinity chromatography have been 
described as simple, one-step methods to purify rhSP–D, they only achieved partial 
purification in the current project (Sorensen et al. 2009, Crouch et al. 2005). Additional 
separation techniques such as ion-exchange chromatography or gel filtration could 
therefore be used to remove additional contaminants (Dodagatta–Marri et al. 2014; 
Sorensen et al. 2009, Kishore et al. 1996; Strong et al. 1998; Crouch et al. 2005; Leth–
Larsen et al. 2005).  
The rhSP–D variants bound strongly to the affinity columns could be eluted by 
competition with typical rhSP–D carbohydrate ligands, based on the preferential 
binding observed by competition ELISA. For example, maltose affinity chromatography 
could be used to purifiy rhSP–D with competitive elution by N–acetylmannosamine 
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(Pohleven et al. 2012).  The partially purified rhSP–D was unstable under long-term 
storage, so the addition of cryoprotectants and proteinase inhibitors might help to 
preserve the protein and inhibit both denaturation and potential degradation (Pierce 
Biotechnology 2005). 
Summary  
 
72 
 
 Summary 6
Human SP–D is a member of the collectins family and was initially identified in the 
lung due to its role in surfactant–mediated innate immunity. Its deficiency can cause 
serious diseases, such as RDS and asthma. Nowadays, commercial surfactants are 
administered during the treatment of pulmonary diseases, but these products do not 
contain hSP–D because this hydrophilic protein is lost during the extraction of 
surfactant from animal lungs. Heterologous expression platforms such as mammalian 
cells and bacteria are used for the production of hSP–D, but the yields are low and the 
cost of production is high when using mammalian cells, and bacteria lack the ability to 
carry out post-translational modifications. Plants offer an alternative system for the 
production of recombinant proteins, allowing large-scale production and a high safety 
profile because they do not support the growth of human pathogens. Recombinant 
proteins may accumulate to higher levels when secreted or directed to intracellular 
compartments, thus affecting post-translational modifications and yields.  
The work described in this thesis focused on the production, purification and 
characterization of three rhSP–D variants (full–size hSP–D, hNCRD, and an hNCRD–
DsRed fusion protein) in tobacco plants. The rhSP–D variants were expressed in the 
apoplast and cytosol to find the best conditions for their production as functional 
proteins. The apoplast was better than the cytosol in terms of rhSP–D yields (30–180 
mg/kg FLW) and transgenic tobacco plants expressing the apoplast-targeted proteins 
showed promise as a sustainable production platform offering higher yields of the rhSP–
D variants (60–80 mg/kg FLW) compared to mammalian cells (~2–5 mg/l) and bacteria 
(~40 mg/l). However, purification of the untagged and His6-tagged rhSP–D variants 
following transient expression revealed challenges involving strong binding of the 
rhSP–D variants to the chromatography resin, which inhibited elution, and the presence 
of plant-derived contaminants, which caused column fouling and interefered with 
binding, together resulting in relatively low yields after purification: ~24 mg/l for 
untagged full-size hSP–D, ~15 mg/l for untagged hNCRD, ~16 mg/l for full-size hSP–D 
with an N-terminal His6 tag, ~27 mg/l for hNCRD with an N-terminal His6 tag, ~2 mg/l 
for full-size hSP–D with a C-terminal His6 tag and ~10 mg/l for hNCRD with a 
C-terminal His6 tag. Competitive ELISA confirmed the lectin-binding activity of the 
untagged and N-terminal His6-tagged full-size hSP–D and hNCRD variants with the 
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same saccharide preferences as the native hSP–D (N-acetylmannosamine followed by 
maltose, glucose and galactose). The rhSP–D variants with C-terminal His6 tags failed 
to bind mannan-coated plates in the competitive ELISA experiments, suggesting the C-
terminal tag blocked the CRD and prevented ligand binding. 
Although only partially-purified rhSP–D variants were obtained, the bacterial 
agglutination assay demonstrated the capacity of the untagged full-size hSP–D and the 
hNCRD–DsRed fusion protein to bind bacterial LPS and induce agglutination. 
Nevertheless, the absorbance values of these two rhSP–D variants were ~2–fold lower 
than the full-size hSP–D control from a murine myeloma cell line, and their activity was 
complete lost after two months in storage at three different temperatures. Further studies 
are therefore required to develop an efficient and economical large-scale purification 
method that can achieve the efficient recovery of pure plant-derived rhSP–D and 
maintain the biological activity of the protein. 
 
 
Annex  
 
74 
 
 Annex 7
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1: pTRApt vector 
SAR: tobacco scaffold attachment region, P35SS/pA35S: 35S promoter with doubled enhancer / 35S 
polyadenylation site and terminator, both from the Cauliflower mosaic virus 35S gene, TL: Tobacco etch 
virus 5ʹ UTR, hSP–D: human surfactant protein D, RB: right border, RK2 ori: origin for A. tumefaciens, 
bla: coding sequence of the -lactamase gene (ampicillin resistance in E. coli and carbenicillin resistance 
in A. tumefaciens), ColE1 ori: origin for E. coli, LB: left border, Pnos/pAnos: promoter/terminator of the 
nopaline synthase gene, pat: bialaphos/phosphinothricin resistance gene,  
 
7.1 List of oligonucleotides 
Table 7.1: Primers used for the cloning and sequencing of rhSP–D variants 
    Name        Target Purpose Sequence 5ʹ → 3ʹ 
SPD–forward Full-size hSP–D Cloning GTCGTCCCATGGACATGCTTTTGTTTCT 
SPD–reverse Full-size hSP–D Cloning CTCGAGGCTGCTGAACTCGCACACAACA
AGTCTTTT 
PS 5ʹ forward 
 
rhSP–D forms Sequencing GACCCTTCCTCTATATAAGG 
 
PS 3ʹ reverse rhSP–D forms Sequencing CACACATTATTCTGGAGAAA 
 
NCRD_NotI_F 
 
Fusion protein Cloning GTCATCGCGGCCGCCGTTGCTAGTCTTA
GACAACAGGTG 
NCRD_XhoI_R Fusion protein Cloning CGATAGCTCGAGTCAAAACTCACAAACC
ACAAGC 
F: forward; R: reverse 
EcoRV 
EcoRV 
BamHI 
SAR 
SAR 
P35SS 
hSP–D 
RB 
RK2ori 
ColE1 ori 
LB 
pat 
pNOS 
pAnos 
bla 
pTRApt_SP–D 
    (8569 bp) 
NcoI 
EcoRI 
EcoRV 
 pA35S 
TL 
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7.2 Sequence of human SP–D  
 
MLLFLLSALVLLTQPLGYLEAEMKTYSHRTMPSACTLVMCSSVESGLPGRDGRDGRE
GPRGEKGDPGLPGAAGQAGMPGQAGPVGPKGDNGSVGEPGPKGDTGPSGPPGPP
GVPGPAGREGALGKQGNIGPQGKPGPKGEAGPKGEVGAPGMQGSAGARGLAGPK
GERGVPGERGVPGNTGAAGSAGAMGPQGSPGARGPPGLKGDKGIPGDKGAKGES
GLPDVASLRQQVEALQGQVQHLQAAFSQYKKVELFPNGQSVGEKIFKTAGFVKPFTE
AQLLCTQAGGQLASPRSAAENAALQQLVVAKNEAAFLSMTDSKTEGKFTYPTGESLV
YSNWAPGEPNDDGGSEDCVEIFTNGKWNDRACGEKRLVVCEF 
Figure 7.2: Amino acidic sequence of the full-size hSP–D protein  
The protein contains 375 amino acids, accession number: AAB59450.1. 
Underline color code: Black:  N-terminal region and signal peptide for secretion, blue: collagenous 
domain, green: α–helical coiled coil neck domain, red: carbohydrate recognition domain.  
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dNTP  
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EDTA 
KDEL 
hSP–D 
hNCRD 
hNCRD–DsRed fusion protein 
Hyb 
His6  
kb  
kDa  
Km 
LB 
LPS  
MES  
mM 
MS 
MW 
NBT 
NCRD  
OD   
Antibody 
5-bromo-4-chloro-3–indolyl-phosphate 
Base pair  
Bovine serum albumin  
Bright Yellow-2  
Cauliflower mosaic virus  
Carbenicillin  
Carbohydrate recogntion domain 
Cultivar  
Deoxyribonucleic acid  
Complementary DNA 
Discosoma sp. red fluorescent protein 
Deoxyribonucleoside triphosphate 
Enzyme-linked immunosorbent assay  
Ethylenediaminetetraacetic acid 
Peptide sequence Lys–Asp–Glu–Leu 
Human SP–D 
Truncated hSP–D (neck + CRD domain) 
hNCRD fusion to DsRed  
Hybridoma 
Polyhistidine tag 
Kilobase 
Kilodalton 
Kanamycin  
Lysogeny broth 
Lipopolysaccharide 
2-(N-morpholino) ethanesulphonic acid  
Millimolar 
Murashige and Skoog  
Molecular weight 
p–Nitroblue tetrazolium chloride 
Truncated SP–D (neck plus CRD domain)  
Optical density  
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Ori  
PAGE  
PBS  
PCR  
pH  
pNPP  
PS 
Rif  
rpm  
SP 
RDS 
rhSP–D  
rSP–D 
SP–D 
SDS–PAGE 
TBE  
TEMED  
Tris  
Tween 20  
U 
UTR  
UV 
v/v 
w/v 
  
Origin of replication 
Polyacrylamide gel electrophoresis  
Phosphate-buffered saline 
Polymerase chain reaction 
A logarithmic measure of hydrogen ion concentration 
Para-nitrophenyl phosphate 
Pulmonary surfactant 
Rifampicin 
Revolutions per minute 
Surfactant protein 
Respiratory distress syndrome 
Recombinant human surfactant protein D 
Recombinant surfactant protein D  
Surfactant protein D  
Sodium dodecylsulfate polyacrylamide gel electrophoresis  
Tris borate EDTA  
N, N, N, N-tetramethylene-ethylenediamine 
Tris(hydroxymethyl)aminomethane 
Polyoxyethylene sorbitan monolaurate  
Units 
Untranslated region 
Ultraviolet 
Volume per volume 
Weight per volume 
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